[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 5392
1. Schwartzbaum JA, Ahlbom A, Lönn S, Warholm M, Rannug A, Auvinen A, Christensen HC, Henriksson R, Johansen C, Lindholm C, Malmer B, Salminen T, Schoemaker MJ, Swerdlow AJ, Feychting M: An international case-control study of glutathione transferase and functionally related polymorphisms and risk of primary adult brain tumors. Cancer Epidemiol Biomarkers Prev; 2007 Mar;16(3):559-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An international case-control study of glutathione transferase and functionally related polymorphisms and risk of primary adult brain tumors.
  • BACKGROUND: Glutathione transferases (GST) detoxify environmental and endogenous compounds and levels of two polymorphic GST proteins, GSTM3 and GSTP1, are high in the brain.
  • Previous studies of GSTM3 and GSTP1 polymorphisms and adult brain tumor risk have produced inconsistent results, whereas the GSTM3 -63 variant is newly identified and, therefore, has not yet been studied in this context.
  • We therefore examined associations between GSTM3 -63, GSTM3 *A/*B, GSTP1 105, and GSTP1 114 variants and adult brain tumor risk and the interaction of the effects of these same polymorphisms with cigarette smoking.
  • In addition, the enzymes NQO1 and CYP1A1 alter susceptibility to oxidative brain damage.
  • RESULTS: We found no associations between the GSTM3, GSTP1, NQO1, CYP1A1, GSTM1, or GSTT1 polymorphisms and adult brain tumor risk with the possible exception of a weak association between the G-C (Val-Ala) GSTP1 105/114 haplotype and glioma [odds ratio (OR), 0.73; 95% confidence interval (95% CI), 0.54, 0.99], nor was there an interaction between the effects of the GSTM3 or GSTP1 polymorphisms and cigarette smoking.
  • CONCLUSIONS: Overall, we observed no strong evidence for an association between GST or related enzyme polymorphisms and adult brain tumor risk.
  • [MeSH-major] Brain Neoplasms / genetics. Glutathione Transferase / genetics. Polymorphism, Genetic
  • [MeSH-minor] Adolescent. Adult. Case-Control Studies. Cytochrome P-450 CYP1A1 / genetics. Denmark / epidemiology. England / epidemiology. Female. Finland / epidemiology. Genotype. Haplotypes. Humans. Logistic Models. Male. Middle Aged. NAD(P)H Dehydrogenase (Quinone) / genetics. Population Surveillance. Risk Factors. Smoking / adverse effects. Sweden / epidemiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17372252.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


2. Micallef J, Taccone M, Mukherjee J, Croul S, Busby J, Moran MF, Guha A: Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression. Cancer Res; 2009 Oct 1;69(19):7548-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme (GBM) is the most common and most malignant adult brain tumor.
  • [MeSH-major] Brain Neoplasms / enzymology. Glioblastoma / enzymology. Membrane Proteins / biosynthesis. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Epidermal Growth Factor / pharmacology. Humans. Intracellular Signaling Peptides and Proteins / genetics. Intracellular Signaling Peptides and Proteins / metabolism. Mice. Neoplasm Invasiveness. Protein Kinase C-alpha / metabolism. RNA, Small Interfering / genetics. Signal Transduction. Transfection

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19773446.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / RNA, Small Interfering; 0 / epidermal growth factor receptor VIII; 125267-21-2 / myristoylated alanine-rich C kinase substrate; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.13 / Protein Kinase C-alpha
  •  go-up   go-down


3. Rajaraman P, Brenner AV, Neta G, Pfeiffer R, Wang SS, Yeager M, Thomas G, Fine HA, Linet MS, Rothman N, Chanock SJ, Inskip PD: Risk of meningioma and common variation in genes related to innate immunity. Cancer Epidemiol Biomarkers Prev; 2010 May;19(5):1356-61
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The etiology of meningioma, the second most common type of adult brain tumor in the United States, is largely unknown.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 AACR
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):976-86 [19223558.001]
  • [Cites] J Immunol. 2009 Mar 1;182(5):3131-8 [19234210.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1651-8 [19423540.001]
  • [Cites] Neurotherapeutics. 2009 Jul;6(3):427-35 [19560733.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2649-58 [10594860.001]
  • [Cites] Neurosurgery. 2000 Nov;47(5):1185-95 [11063113.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):79-86 [11150357.001]
  • [Cites] Cancer Lett. 2002 Dec 15;188(1-2):103-7 [12406554.001]
  • [Cites] Genet Epidemiol. 2003 Dec;25(4):360-6 [14639705.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):789-96 [14685227.001]
  • [Cites] J Anat. 2005 Sep;207(3):265-9 [16185251.001]
  • [Cites] Nat Rev Immunol. 2005 Nov;5(11):866-79 [16261174.001]
  • [Cites] Immunol Rev. 2006 Oct;213:195-212 [16972905.001]
  • [Cites] Pharmacogenet Genomics. 2006 Nov;16(11):783-8 [17047486.001]
  • [Cites] Am J Epidemiol. 2007 Mar 1;165(5):477-85 [17182979.001]
  • [Cites] Histol Histopathol. 2007 Dec;22(12):1387-98 [17701919.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 17;99(20):1544-50 [17925535.001]
  • [Cites] PLoS Genet. 2008 Aug;4(8):e1000166 [18846228.001]
  • [Cites] Dement Geriatr Cogn Disord. 2008;26(3):247-50 [18841008.001]
  • [Cites] PLoS One. 2009;4(4):e5360 [19390683.001]
  • (PMID = 20406964.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01CO12400; United States / Intramural NIH HHS / / Z99 CA999999; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS184299; NLM/ PMC3169167
  •  go-up   go-down


Advertisement
4. Schubart JR, Kinzie MB, Farace E: Caring for the brain tumor patient: family caregiver burden and unmet needs. Neuro Oncol; 2008 Feb;10(1):61-72
MedlinePlus Health Information. consumer health - Caregivers.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caring for the brain tumor patient: family caregiver burden and unmet needs.
  • The rapid onset and progression of a brain tumor, cognitive and behavioral changes, and uncertainty surrounding prognosis are issues well known to health practitioners in neuro-oncology.
  • We studied the specific challenges that family caregivers face when caring for patients experiencing the significant neurocognitive and neurobehavioral disorders associated with brain tumors.
  • We selected 25 family caregivers of adult brain tumor patients to represent the brain tumor illness trajectory (crisis, chronic, and terminal phases).
  • [MeSH-major] Brain Neoplasms. Caregivers / statistics & numerical data. Cost of Illness. Family Relations
  • [MeSH-minor] Adult. Aged. Female. Health Services Needs and Demand. Humans. Male. Middle Aged. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Res Nurs Health. 2006 Apr;29(2):105-20 [16532486.001]
  • [Cites] Eur J Cancer Care (Engl). 1999 Jun;8(2):83-6 [10476110.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1999;11(4):225-31 [10473718.001]
  • [Cites] Patient Educ Couns. 2005 Jun;57(3):247-9 [15893205.001]
  • [Cites] Patient Educ Couns. 2005 Jun;57(3):250-61 [15893206.001]
  • [Cites] Patient Educ Couns. 2005 Jul;58(1):96-103 [15950842.001]
  • [Cites] Patient Educ Couns. 2005 Aug;58(2):182-6 [16009294.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):357-61 [10831342.001]
  • [Cites] Patient Educ Couns. 1999 Nov;38(3):217-25 [10865687.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3295-301 [10986063.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):152-8 [11465395.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2001;13(3):204-8 [11527297.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18 Suppl):61S-63S [11560975.001]
  • [Cites] Nurs Econ. 2002 Sep-Oct;20(5):216-21, 224 [12382538.001]
  • [Cites] Nurs Inq. 2004 Mar;11(1):43-53 [14962346.001]
  • [Cites] Cancer Nurs. 1989 Oct;12(5):285-92 [2804964.001]
  • [Cites] Oncol Nurs Forum. 1996 Sep;23(8):1247-56 [8883072.001]
  • [Cites] J Neurosci Nurs. 1998 Aug;30(4):245-52 [9791779.001]
  • [Cites] Support Care Cancer. 2006 Dec;14(12):1258-61 [16775683.001]
  • (PMID = 17993635.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2600839
  •  go-up   go-down


5. Lu Z, Zhou L, Killela P, Rasheed AB, Di C, Poe WE, McLendon RE, Bigner DD, Nicchitta C, Yan H: Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress. Cancer Res; 2009 Dec 1;69(23):9105-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress.
  • Glioblastoma multiforme is the most prevalent type of adult brain tumor and one of the deadliest tumors known to mankind.
  • The genetic understanding of glioblastoma multiforme is, however, limited, and the molecular mechanisms that facilitate glioblastoma multiforme cell survival and growth within the tumor microenvironment are largely unknown.
  • The small interfering RNA-mediated knockdown of SEC61gamma expression in tumor cells led to growth suppression and apoptosis.
  • Together, these results indicate that aberrant expression of SEC61gamma serves significant roles in glioblastoma multiforme cell survival likely via a mechanism that is involved in the cytoprotective ER stress-adaptive response to the tumor microenvironment.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prog Clin Biol Res. 1994;385:51-7 [7972237.001]
  • [Cites] Nucleic Acids Res. 1994 Jan 25;22(2):187-93 [8121803.001]
  • [Cites] Genomics. 1996 Feb 15;32(1):97-103 [8786126.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Feb;15(2):134-7 [8834178.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Dec;17(4):205-14 [8946202.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3322-31 [9345014.001]
  • [Cites] Oncogene. 1998 Jan 15;16(2):191-5 [9464536.001]
  • [Cites] Oncogene. 1998 May;16(20):2617-27 [9632138.001]
  • [Cites] J Cell Sci. 1999 May;112 ( Pt 10):1477-86 [10212142.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8505-10 [10411905.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12):966-77 [15573118.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):919-24 [15705891.001]
  • [Cites] Oncogene. 2005 Apr 7;24(15):2495-502 [15735698.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4051-8 [15899794.001]
  • [Cites] Carcinogenesis. 2005 Aug;26(8):1374-81 [15845651.001]
  • [Cites] EMBO J. 2005 Oct 5;24(19):3470-81 [16148948.001]
  • [Cites] Annu Rev Cell Dev Biol. 2005;21:529-50 [16212506.001]
  • [Cites] Mol Cancer Res. 2005 Nov;3(11):597-605 [16317085.001]
  • [Cites] Cell Death Differ. 2006 Mar;13(3):374-84 [16397578.001]
  • [Cites] Mol Cancer Res. 2006 Mar;4(3):169-76 [16547154.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3935-41 [16818690.001]
  • [Cites] Mol Cancer Res. 2006 Jul;4(7):423-36 [16849518.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):721-2 [16880733.001]
  • [Cites] EMBO Rep. 2006 Sep;7(9):880-5 [16953201.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:487-508 [16822172.001]
  • [Cites] Trends Mol Med. 2006 Dec;12(12):567-73 [17071140.001]
  • [Cites] Mol Biol Cell. 2007 Mar;18(3):1064-72 [17215517.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jul;8(7):519-29 [17565364.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9809-16 [17942911.001]
  • [Cites] Cell Mol Life Sci. 2008 Mar;65(6):862-94 [18038217.001]
  • [Cites] Bioessays. 2000 Aug;22(8):697-707 [10918300.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Nov;29(3):207-12 [10992295.001]
  • [Cites] Endocr Relat Cancer. 2001 Jun;8(2):83-96 [11397666.001]
  • [Cites] Biochem Soc Trans. 2001 Aug;29(Pt 4):480-4 [11498013.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45307-19 [11535584.001]
  • [Cites] Neuro Oncol. 2002 Apr;4(2):86-94 [11916499.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16156-61 [12461184.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):723-7 [12566319.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6962-70 [14583498.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3089-94 [14970324.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1926-33 [15143086.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903 [3477813.001]
  • [Cites] J Neuropathol Exp Neurol. 1988 May;47(3):191-205 [3367154.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2965-9 [1557402.001]
  • [Cites] Genomics. 1992 May;13(1):16-20 [1349571.001]
  • [Cites] Genomics. 1992 May;13(1):21-4 [1315716.001]
  • [Cites] Cell Growth Differ. 1993 Dec;4(12):1065-70 [8117620.001]
  • [Cites] Genomics. 1995 Aug 10;28(3):367-76 [7490069.001]
  • (PMID = 19920201.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01CA118822; United States / NCI NIH HHS / CA / P50 CA108786; United States / NINDS NIH HHS / NS / P50 NS020023; United States / NINDS NIH HHS / NS / 5P50 NS20023; United States / NCI NIH HHS / CA / R37 CA 011898; United States / NCI NIH HHS / CA / R01 CA118822-04; United States / NCI NIH HHS / CA / 5P50 CA108786; United States / NCI NIH HHS / CA / R01 CA118822; United States / NCI NIH HHS / CA / R37 CA011898; United States / NCI NIH HHS / CA / CA118822-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / RNA, Small Interfering; 0 / SEC61G protein, human; 11089-65-9 / Tunicamycin; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ NIHMS151081; NLM/ PMC2789175
  •  go-up   go-down


6. Rajaraman P, Brenner AV, Butler MA, Wang SS, Pfeiffer RM, Ruder AM, Linet MS, Yeager M, Wang Z, Orr N, Fine HA, Kwon D, Thomas G, Rothman N, Inskip PD, Chanock SJ: Common variation in genes related to innate immunity and risk of adult glioma. Cancer Epidemiol Biomarkers Prev; 2009 May;18(5):1651-8
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common variation in genes related to innate immunity and risk of adult glioma.
  • Current evidence suggests that immune system alterations contribute to the etiology of adult glioma, the most common adult brain tumor.

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Immunol. 2007 Mar;28(3):138-45 [17276138.001]
  • [Cites] Free Radic Biol Med. 2008 Dec 1;45(11):1501-9 [18790046.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1229-35 [17548690.001]
  • [Cites] Nature. 2007 Jun 7;447(7145):655-60 [17554299.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 17;99(20):1544-50 [17925535.001]
  • [Cites] J Mol Med (Berl). 2007 Nov;85(11):1271-80 [17634906.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):79-86 [11150357.001]
  • [Cites] Am J Hum Genet. 2002 Feb;70(2):425-34 [11791212.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):609-15 [11920623.001]
  • [Cites] Int J Cancer. 2002 May 10;99(2):252-9 [11979441.001]
  • [Cites] Hum Mutat. 2002 Jul;20(1):1-14 [12112652.001]
  • [Cites] Amyotroph Lateral Scler Other Motor Neuron Disord. 2002 Jun;3(2):69-74 [12215228.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):423-8 [12845684.001]
  • [Cites] Genet Epidemiol. 2003 Dec;25(4):360-6 [14639705.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):789-96 [14685227.001]
  • [Cites] J Med Genet. 2004 May;41(5):334-41 [15121769.001]
  • [Cites] Clin Chem. 1985 Jan;31(1):164-5 [3965205.001]
  • [Cites] Cancer. 1992 May 15;69(10):2541-7 [1568177.001]
  • [Cites] Epidemiology. 1993 Jul;4(4):295-302 [8347739.001]
  • [Cites] Mol Biol Evol. 1995 Sep;12(5):921-7 [7476138.001]
  • [Cites] Methods Enzymol. 1996;272:199-210 [8791778.001]
  • [Cites] Int J Cancer. 1999 Jul 19;82(2):155-60 [10389745.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8468-73 [15548720.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6459-65 [16024651.001]
  • [Cites] Nat Rev Immunol. 2005 Nov;5(11):866-79 [16261174.001]
  • [Cites] Cell Mol Life Sci. 2006 Mar;63(6):709-22 [16465451.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4531-41 [16618782.001]
  • [Cites] Nat Genet. 2006 Aug;38(8):904-9 [16862161.001]
  • [Cites] Int J Cancer. 2006 Nov 1;119(9):2165-72 [16823851.001]
  • [Cites] Immunol Rev. 2006 Oct;213:48-65 [16972896.001]
  • [Cites] Immunol Rev. 2006 Oct;213:195-212 [16972905.001]
  • [Cites] J Agric Saf Health. 2006 Nov;12(4):255-74 [17131948.001]
  • [Cites] Trends Immunol. 2007 Jan;28(1):12-8 [17129764.001]
  • [Cites] J Clin Neurosci. 2007 Nov;14(11):1041-8 [17954373.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2448-54 [18006935.001]
  • [Cites] Carcinogenesis. 2007 Dec;28(12):2543-7 [17916900.001]
  • [Cites] Genet Epidemiol. 2007 Dec;31(8):803-12 [17549762.001]
  • [Cites] Arthritis Rheum. 2007 Dec;56(12):4164-73 [18050247.001]
  • [Cites] Amyotroph Lateral Scler. 2008 Apr;9(2):108-19 [18428003.001]
  • [Cites] PLoS One. 2008;3(7):e2551 [18596976.001]
  • [Cites] J Am Coll Cardiol. 2007 May 15;49(19):1934-42 [17498578.001]
  • (PMID = 19423540.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01CO12400; United States / Intramural NIH HHS / / Z01 CP010135-12; United States / PHS HHS / / N01-C0-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5-Lipoxygenase-Activating Proteins; 0 / ALOX5AP protein, human; 0 / Carrier Proteins; 0 / Cytoskeletal Proteins; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / ITGB1BP2 protein, human; 0 / LY96 protein, human; 0 / Lymphocyte Antigen 96; 0 / Membrane Proteins; 0 / Muscle Proteins; 0 / NF-kappa B p50 Subunit; 0 / NFKB1 protein, human; 0 / Neuropeptides; 0 / STAT1 Transcription Factor; 0 / STAT1 protein, human; 0 / Selenoprotein P; 0 / Serpins; 0 / beta-Defensins; 0 / neuroserpin; EC 1.15.1.- / superoxide dismutase 1; EC 1.15.1.1 / Superoxide Dismutase; EC 1.6.3.1 / NADPH Oxidase; EC 1.6.3.1 / NCF2 protein, human; EC 2.7.11.1 / IRAK3 protein, human; EC 2.7.11.1 / Interleukin-1 Receptor-Associated Kinases
  • [Other-IDs] NLM/ NIHMS117439; NLM/ PMC2771723
  •  go-up   go-down


7. Fisher JL, Schwartzbaum JA, Wrensch M, Berger MS: Evaluation of epidemiologic evidence for primary adult brain tumor risk factors using evidence-based medicine. Prog Neurol Surg; 2006;19:54-79
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of epidemiologic evidence for primary adult brain tumor risk factors using evidence-based medicine.
  • We evaluate genetic, behavioral, developmental and experiential risk factors for primary adult brain tumors (primarily, astrocytoma and meningioma) using a systematic set of principles adapted from evidence-based medicine standards.
  • In addition to ionizing radiation, rare mutations in highly penetrant genes associated with certain diseases/syndromes, and epilepsy and seizures (which probably result from, rather than cause, adult brain tumors), only the unexplained observation of familial aggregation of astrocytoma has been consistently shown.
  • There is promising renewed interest in associations between infections, allergic conditions and adult brain tumor risk.
  • Our knowledge of the causes of adult brain tumors is limited and should be expanded by results from large, well-designed studies of novel potential risk factors and potential interactions between known and suspected risk factors.
  • [MeSH-major] Brain Neoplasms / etiology. Epidemiologic Methods. Evidence-Based Medicine / methods

  • Genetic Alliance. consumer health - Brain Tumor, Adult.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033147.001).
  • [ISSN] 0079-6492
  • [Journal-full-title] Progress in neurological surgery
  • [ISO-abbreviation] Prog Neurol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 142
  •  go-up   go-down


8. Crom DB: "I think you are pretty; i don't know why everyone can't see that": reflections from a young adult brain tumor survivor camp. J Clin Oncol; 2009 Jul 1;27(19):3259-61
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "I think you are pretty; i don't know why everyone can't see that": reflections from a young adult brain tumor survivor camp.
  • [MeSH-major] Brain Neoplasms / psychology. Survivors / psychology
  • [MeSH-minor] Humans. Young Adult

  • Genetic Alliance. consumer health - Brain Tumor, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19364949.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Padovani L, André N, Carrie C, Muracciole X: [Childhood and adult medulloblastoma: what difference?]. Cancer Radiother; 2009 Oct;13(6-7):530-5
Genetic Alliance. consumer health - Medulloblastoma, childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Childhood and adult medulloblastoma: what difference?].
  • Medulloblastoma is the most frequent childhood brain tumor (30%) but account only for less than 1% of adult brain tumor.
  • Due to the rarety in adult population, no prospective studies and few data about late effects are available.
  • Adult medulloblastoma is a therapeutic challenge and their therapeutic strategies are similar to pediatric protocols.
  • In order to improve the understanding of adult disease and to homogenize the treatment, National Cancer Institute (INCa) stimulated the creation of web conference to discuss each case prospectively and to propose a protocol of treatment.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Medulloblastoma / pathology
  • [MeSH-minor] Adult. Age Factors. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Brain Neoplasms / epidemiology. Child. Cognition Disorders / epidemiology. Cognition Disorders / etiology. Combined Modality Therapy. France / epidemiology. Humans. Incidence. Molecular Biology / methods. Radiotherapy / adverse effects. Radiotherapy / methods. Surgical Procedures, Operative

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19713143.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Connelly JM, Malkin MG: Environmental risk factors for brain tumors. Curr Neurol Neurosci Rep; 2007 May;7(3):208-14
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Environmental risk factors for brain tumors.
  • Primary brain tumors, whether malignant or nonmalignant, have devastating consequences.
  • Despite decades of epidemiologic research to identify environmental causes of brain tumors, very little progress has been made.
  • The purpose of this paper is to review the most recent studies in the epidemiology of brain tumors.
  • Popular topics of interest in adult brain tumor epidemiology include electromagnetic fields (particularly cellular phones), occupational exposures, nitroso-containing compounds (especially smoking), hair products, and allergic and immunologic factors.
  • Some of these topics are also applicable to the etiology of childhood brain tumors, but additional areas of interest in the pediatric population focus on parental exposure prior to conception, maternal exposure during pregnancy, and childhood exposure to infectious agents.
  • Although there are many proposed associations with brain tumors, none possess the statistical significance to confidently ascribe causation.
  • [MeSH-major] Brain Neoplasms. Environmental Exposure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488586.001).
  • [ISSN] 1528-4042
  • [Journal-full-title] Current neurology and neuroscience reports
  • [ISO-abbreviation] Curr Neurol Neurosci Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hair Dyes; 0 / Nitroso Compounds
  • [Number-of-references] 47
  •  go-up   go-down


11. Keir ST, Swartz JJ, Friedman HS: Stress and long-term survivors of brain cancer. Support Care Cancer; 2007 Dec;15(12):1423-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stress and long-term survivors of brain cancer.
  • INTRODUCTION: Adult brain tumor patients are joining the ranks of cancer survivors in increasing numbers in the United States.
  • METHODS: Using the Perceived Stress Scale and the National Comprehensive Cancer Network's Distress Thermometer, levels of stress and cancer-related items of concern were assessed in adult long-term survivors of brain cancer.
  • Scores were not significantly associated with age, gender, treatment status, or tumor grade.
  • Long-term survivors were just as likely to report being stressed (chi(2) = 0.032, NS), while reporting fewer numbers of items of concern (5.02, SD = 3.509), compared to brain tumor patients diagnosed 18 months (M = 6.82, SD = 3.737, t = 2.467, p 0.05).
  • DISCUSSION/CONCLUSION: Despite their long-term survival status, long-term survivors of brain cancer continue to experience elevated levels of stress.
  • IMPLICATIONS FOR BRAIN TUMOR SURVIVORS: This study provides a better understanding of the unique needs of long-term survivors of brain cancer.
  • [MeSH-major] Brain Neoplasms / mortality. Stress, Psychological / complications
  • [MeSH-minor] Adult. Aged. Female. Health Status Indicators. Humans. Male. Middle Aged. Psychological Tests. Psychometrics. Quality of Life. Time Factors

  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stress.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17609991.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Zitron IM, Norkina O, Al-Kadhimi Z, Barger GR, Lum LG, Mittal S: Targeting of glioblastoma with activated T cells armed with anti-CD3xanti-HER2/neu (HER2Bi) and anti-CD3xanti-EGFR (EGFRBi) bispecific antibodies. J Clin Oncol; 2009 May 20;27(15_suppl):3038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3038 Background: Malignant gliomas are the most common primary brain tumors in adults.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962074.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Shen S, Nabors LB, Raizer JJ, Fiveash JB, Spies S, Costello R, O'Neill AM: Dosimetry study of a phase II multiple-dose intracavitary administration of <sup>131</sup>I-TM601 in adult patients with recurrent high-grade glioma. J Clin Oncol; 2009 May 20;27(15_suppl):e13006

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dosimetry study of a phase II multiple-dose intracavitary administration of <sup>131</sup>I-TM601 in adult patients with recurrent high-grade glioma.
  • Dose escalation of external beam radiotherapy or brachytherapy is limited by normal brain radionecrosis.
  • Radiolabeled targeting molecules can deliver localized radiation to tumor and reduce normal brain radionecrosis.
  • TM601, or synthetic Chlorotoxin, is a peptide derived from scorpion venom that specifically binds to tumor cells.
  • Here we report dosimetry results of an imaging sub-study of a phase II trial, in which weekly doses of <sup>131</sup>I-TM601 were infused into surgically created tumor resection cavities for 3 or 6 weeks.
  • For each imaging study, 5 sequential SPECT images (1-168 hour) were registered with MRI to determine the <sup>131</sup>I-TM601 radiation dose to the 2-cm tumor cavity margin.
  • Median tumor cavity volume was 11.4 mL, and ranged 5.2 - 35.5 mL.
  • These results support the multi-dose fractionation scheme for <sup>131</sup>I-TM601 to minimize normal tissue toxicity, including radiation necrosis, and extend continuous irradiation to clinical or sub-clinical residual tumor cells after surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962762.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Pistollato F, Abbadi S, Rampazzo E, Viola G, Della Puppa A, Cavallini L, Panchision DM, Te Kronnie G, Basso G: Glioblastoma-derived cells exhibit differential responses to glycolysis inhibition under hypoxia. J Clin Oncol; 2009 May 20;27(15_suppl):e13031

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e13031 It has been suggested that oxygen tension is a crucial component of the brain tumor niche, as hypoxia positively correlates with tumor aggressiveness and over-activity of hypoxia inducible factor-1α (HIF-1α) reinforces tumor progression.
  • Our results show that adult GBM displaying a highly immature phenotype manifested the highest resistance to glucose deprivation.
  • Also, hypoxia inhibits the mitochondria-controlled apoptosis induced by 2-DG, by conferring cell resistance through progressive activation of pro-survival NF-kB and induction of tumor cell autophagy.
  • These results indicate differences in tumor cells behavior that may be predictive of cell response to therapy aiming to limit glucose uptake or glucose metabolism.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962877.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Marcy P Sr, Chamorey E, Macchiavello J, Largillier R, Peyrade F, Ferrero J, Hanoun-Levi J, Poudenx M, François E, Frenay M: Distal or proximal venous port device insertion: Results of a prospective randomized trial. J Clin Oncol; 2009 May 20;27(15_suppl):e20605

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eligibility criteria included adult patients with solid tissue malignancy (neuro oncology, gynecology, lung, abdominal, head§neck) beginning a course of I.V.chemotherapy, normal hemostatic parameters, no organ failure, a life expectancy >3months, WHO status<3.
  • Exclusion criteria included current anticoagulant therapy, previous ipsilateral venous catheter/pacewires/surgical axillary node dissection/radiodermatitis, local tumor growth/sepsis, symptomatic brain metastasis, psychosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961555.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Green RM, Cloughesy T, Stupp R, DeAngelis LM, Woyshner EA, Ney DE, Lassman AB: Bevacizumab for recurrent ependymoma. J Clin Oncol; 2009 May 20;27(15_suppl):2060

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2060 Background: Ependymoma is a rare type of glioma, representing less than 5% of brain tumors in adults.
  • METHODS: We retrospectively identified adults treated for recurrent ependymoma and anaplastic ependymoma with bevacizumab containing chemotherapy regimens.
  • Bevacizumab (5-10 mg/kg) every other week was combined with cytotoxic agents: irinotecan (3), carboplatin (2), or temozolomide (1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964675.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Horbinski C, Mintz A, Engh J, Lieberman F, Hamilton RL, Park DM: Post-therapeutic changes in the molecular profile of glioblastomas. J Clin Oncol; 2009 May 20;27(15_suppl):2026

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2026 Background: Glioblastoma multiforme is the most common and malignant primary brain tumor in adults.
  • Analyses were performed on tumor tissue obtained at initial diagnosis and at first recurrence.
  • 24% of previously non-EGFR-amplified tumors acquired low-grade amplification (less than 10 copies/chromosome 7 CEP signal) after treatment, and 16% of EGFR-amplified tumors lost amplification after treatment.
  • CONCLUSIONS: Our results suggest that the molecular profile of these tumors is dynamic and that certain key alterations, including acquisition of low-level EGFR amplification in previously EGFR-negative tumors, occurs in a subset of cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964598.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Pfister SM, Remke M, Benner A, Werft W, Mendrzyk F, Scheurlen W, Kulozik A, Lichter P, Korshunov A: Use of CDK6 oncogene amplification and 17q gain to predict poor clinical risk groups in adult medulloblastoma. J Clin Oncol; 2009 May 20;27(15_suppl):2030

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of CDK6 oncogene amplification and 17q gain to predict poor clinical risk groups in adult medulloblastoma.
  • : 2030 Background: While in children medulloblastoma comprises the most common malignant brain tumor, it accounts for only 1% of intracranial malignancies in adults.
  • The infrequent appearance of MB in adults poses the question, whether these tumors are the same in adults and children in terms of biological and clinical peculiarities.
  • METHODS: Array-CGH was performed for a total 34 adult medulloblastoma samples (>18 years) and results were compared with data from 101 pediatric patients.
  • Selected genomic regions were further investigated by FISH analysis in an independent cohort of 415 samples (112 adult and 303 pediatric).
  • All 146 adult patients received a standard treatment regimen consisting of tumor resection, irradiation of the neuroaxis with 36 Gy, a boost of 20-23 Gy to the posterior fossa, and eight cycles of vincristin, lomustine, and cisplatin.
  • RESULTS: Copy-number gains of chromosome 17q as well as high-level amplifications of CDK6 were identified as significant adverse prognostic markers in adult medulloblastoma.
  • Apart from one exception, CDK6 amplifications were only observed in adult patients (9% in adults versus 0.2 % in children), whereas amplifications of MYC or MYCN were significantly overrepresented in the pediatric cohort, but when present were also associated with dismal prognosis in adults.
  • Based on these results, we propose a molecular staging system for adult medulloblastoma: i) cases with oncogene amplification (10% of cases, 5-year OS = 0%);.
  • CONCLUSIONS: We report on the largest cohort of adult medulloblastoma investigated for genomic imbalances to date.
  • We propose a model for the molecular risk stratification of adult medulloblastoma comprising three distinct genomic risk groups with significantly different survival and tumor biology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964634.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Lu DY, Leung YM, Huang SM, Wong KL: Bradykinin-induced cell migration and COX-2 production mediated by the bradykinin B1 receptor in glioma cells. J Cell Biochem; 2010 May;110(1):141-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent reports have also shown that bradykinin selectively modulates blood-tumor barrier permeability.
  • Glioma is the most common primary adult brain tumor, with a poor prognosis because of the ease with which tumor cells spread to other regions of the brain.
  • [MeSH-minor] Animals. Cell Line, Tumor. Gene Expression Regulation, Neoplastic / drug effects. Humans. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Rats. Signal Transduction / drug effects. Transcription Factor AP-1 / metabolism. Up-Regulation / drug effects


20. Yeh WL, Lu DY, Lee MJ, Fu WM: Leptin induces migration and invasion of glioma cells through MMP-13 production. Glia; 2009 Mar;57(4):454-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, leptin has been found in many tumor cell lines and has been shown to have mitogenic and angiogenic activity in a number of cell types.
  • Glioma is the most common primary adult brain tumor with poor prognosis because of the spreading of tumor cell to the other regions of brain easily.
  • [MeSH-major] Brain Neoplasms / metabolism. Cell Movement / physiology. Gene Expression Regulation, Neoplastic / physiology. Glioma / metabolism. Leptin / physiology. Matrix Metalloproteinase 13 / metabolism
  • [MeSH-minor] Animals. Antibodies / pharmacology. Astrocytes. Cell Line, Tumor. Dose-Response Relationship, Drug. Enzyme Inhibitors / pharmacology. Humans. Neoplasm Invasiveness / genetics. Protein-Serine-Threonine Kinases / metabolism. RNA, Messenger / metabolism. Rats. Receptors, Leptin / genetics. Receptors, Leptin / metabolism. Signal Transduction / drug effects. Signal Transduction / genetics. Transfection. p38 Mitogen-Activated Protein Kinases / metabolism

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18814267.001).
  • [ISSN] 1098-1136
  • [Journal-full-title] Glia
  • [ISO-abbreviation] Glia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Enzyme Inhibitors; 0 / Leptin; 0 / RNA, Messenger; 0 / Receptors, Leptin; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 2.7.11.25 / NF-kappa B kinase; EC 3.4.24.- / Matrix Metalloproteinase 13
  •  go-up   go-down


26. Ferrer S: [Radiation therapy with synchrotron radiation and cisplatin-based chemotherapy as a treatment of gliomas]. Med Clin (Barc); 2005 Feb 26;124(7):271-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Esteve has been working for several years in the Grenoble Synchrotron (ESRF) on radiotherapy treatments to heal brain tumors.
  • Gliomas the commonest brain tumor in the adult and the mean survival in advanced disease patients is lower than one year.
  • Conventional radiation therapy is used palliatively since it is one of the most radiotherapy-resistant tumors.
  • Experiments at the Grenoble Synchrotron have been carried out in mice with gliomas and they consist of injecting cysplatine into the tumors so that an intense monochromatic radiation is applied afterwards.
  • After one year of treatment, 34% of animals remain alive, which constitutes a result never seen before in this type of radio-resistant tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Cisplatin / therapeutic use. Glioma / drug therapy. Glioma / radiotherapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15743595.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Becker H: [Intracerebral hemorrhage misjudged as tumor]. Clin Neuroradiol; 2010 Aug;20(3):161-4
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracerebral hemorrhage misjudged as tumor].
  • [Transliterated title] Intrazerebrale Blutung als Tumor verkannt.
  • The patient was informed that she had a tumor.
  • [MeSH-major] Brain Neoplasms / radiography. Cerebral Hemorrhage / radiography. Diagnostic Errors / prevention & control. Hemangioma, Cavernous, Central Nervous System / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20625692.001).
  • [ISSN] 1869-1447
  • [Journal-full-title] Clinical neuroradiology
  • [ISO-abbreviation] Clin Neuroradiol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Aghi M, Barker FG 2nd: Benign adult brain tumors: an evidence-based medicine review. Prog Neurol Surg; 2006;19:80-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign adult brain tumors: an evidence-based medicine review.
  • BACKGROUND: Benign adult brain tumors can be managed conservatively or using surgery, radiation, or medicines.
  • While randomized comparisons assessing tumor recurrence, quality of life, or survival are the ideal means of comparing treatments, it can be difficult to recruit patients to such trials and lengthy follow-up periods are needed because of the slowly progressive natural history of these tumors.
  • METHODS: Review of the literature on benign adult brain tumors using evidence-based standards and focusing on meningiomas, pituitary adenomas, and vestibular schwannomas, which together represent the majority of WHO grade 1 adult brain tumors.
  • RESULTS: Nearly all studies of benign adult brain tumors were of relatively poor quality (level 3 or poorer).
  • CONCLUSIONS: While randomized clinical trials comparing conservative management, surgery, radiation, and medical management of benign adult benign tumors are unlikely to occur, there is some level 3 evidence that can assist in their treatment.
  • [MeSH-major] Brain Neoplasms / therapy. Evidence-Based Medicine
  • [MeSH-minor] Adenoma / therapy. Adult. Humans. Meningeal Neoplasms / therapy. Meningioma / therapy. Neuroma, Acoustic / therapy. Neurosurgical Procedures. Phototherapy. Pituitary Neoplasms / therapy. Radiosurgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033148.001).
  • [ISSN] 0079-6492
  • [Journal-full-title] Progress in neurological surgery
  • [ISO-abbreviation] Prog Neurol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 58
  •  go-up   go-down


29. Weller M: [Chemotherapy for brain tumors in adult patients]. Nervenarzt; 2008 Feb;79(2):231-41
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy for brain tumors in adult patients].
  • Chemotherapy has become a third major treatment option for patients with brain tumors, in addition to surgery and radiotherapy.
  • Several ongoing trials seek to define the role of chemotherapy in the primary care of other gliomas.
  • Outside such clinical trials chemotherapy is used in addition to radiotherapy, e.g., in anaplastic astrocytoma, medulloblastoma or germ cell tumors, or as an alternative to radiotherapy, e.g., in anaplastic oligodendroglial tumors or low-grade gliomas.
  • In contrast, there is no established role for chemotherapy in other tumors such as ependymomas, meningiomas or neurinomas.
  • Primary cerebral lymphomas are probably the only brain tumors which can be cured by chemotherapy alone and only by chemotherapy.
  • The chemotherapy of brain metastases follows the recommendations for the respective primary tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Lymphoma / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Combined Modality Therapy. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Genetic Markers / genetics. Humans. Prognosis. Promoter Regions, Genetic / genetics. Topotecan / adverse effects. Topotecan / therapeutic use. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18253773.001).
  • [ISSN] 0028-2804
  • [Journal-full-title] Der Nervenarzt
  • [ISO-abbreviation] Nervenarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Genetic Markers; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 7M7YKX2N15 / Topotecan; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


30. Young GS: Advanced MRI of adult brain tumors. Neurol Clin; 2007 Nov;25(4):947-73, viii
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced MRI of adult brain tumors.
  • This article is intended to provide clinical neurologists with an overview of the major techniques of advanced MRI of brain tumor: diffusion-weighted imaging, perfusion-weighted imaging, dynamic contrast-enhanced T1 permeability imaging, diffusion-tensor imaging, and magnetic resonance spectroscopy.
  • These techniques represent a significant addition to conventional anatomic MRI T2-weighted images, fluid attenuated inversion recovery (FLAIR) T2-weighted images, and gadolinium-enhanced T1-weighted images for assessing tumor cellularity, white matter invasion, metabolic derangement including hypoxia and necrosis, neovascular capillary blood volume, and permeability.
  • Although a brief introduction and more extensive references to the technical literature is provided, the major focus is to provide a summary of recent clinical experience in application of these major advanced MRI techniques to differential diagnosis, grading, surgical planning, and monitoring of therapeutic response of tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Magnetic Resonance Spectroscopy. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964022.001).
  • [ISSN] 0733-8619
  • [Journal-full-title] Neurologic clinics
  • [ISO-abbreviation] Neurol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 123
  •  go-up   go-down


31. Stienen MN, Hermann C, Breuer T, Gautschi OP: [Pott's puffy tumor - severe course of a sinusitis]. Praxis (Bern 1994); 2010 Apr 28;99(9):555-60
MedlinePlus Health Information. consumer health - Sinusitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pott's puffy tumor - severe course of a sinusitis].
  • [Transliterated title] Pott's puffy-Tumor - Schwerer Verlauf einer Sinusitis.
  • [MeSH-major] Brain Edema. Frontal Bone. Osteomyelitis. Sinusitis / complications
  • [MeSH-minor] Adult. Anti-Bacterial Agents / administration & dosage. Anti-Bacterial Agents / therapeutic use. Brain Abscess / etiology. Craniotomy. Emergencies. Empyema, Subdural / etiology. Hospitalization. Humans. Length of Stay. Magnetic Resonance Imaging. Male. Meningoencephalitis / complications. Meningoencephalitis / diagnosis. Meningoencephalitis / surgery. Time Factors. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20449824.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


32. Sauvageot CM, Kesari S, Stiles CD: Molecular pathogenesis of adult brain tumors and the role of stem cells. Neurol Clin; 2007 Nov;25(4):891-924, vii
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathogenesis of adult brain tumors and the role of stem cells.
  • Primary brain tumors consist of neoplasms with varied molecular defects, morphologic phenotypes, and clinical outcomes.
  • The genetic and signaling abnormalities involved in tumor initiation and progression of the most prevalent adult primary brain tumors, including gliomas, meningiomas, and medulloblastomas, are described in this article.
  • The current understanding of the cell-of-origin of these neoplasms is reviewed, which suggests that the malignant phenotype is propelled by cells with stem-like qualities.
  • A comprehensive understanding of the molecular basis of transformation and the cell-of-origin of these neoplasms will enable the formulation of more targeted treatment alternatives that could improve survival and quality of life.
  • [MeSH-major] Brain Neoplasms / pathology. Stem Cells / pathology. Stem Cells / physiology
  • [MeSH-minor] Adult. Genes, p53 / genetics. Humans. Intercellular Signaling Peptides and Proteins / genetics. Phenotype. RNA, Messenger / genetics. Signal Transduction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964020.001).
  • [ISSN] 0733-8619
  • [Journal-full-title] Neurologic clinics
  • [ISO-abbreviation] Neurol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Messenger
  • [Number-of-references] 272
  •  go-up   go-down


33. Liu HE, Hsiao PY, Lee CC, Lee JA, Chen HY: NAT2*7 allele is a potential risk factor for adult brain tumors in Taiwanese population. Cancer Epidemiol Biomarkers Prev; 2008 Mar;17(3):661-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NAT2*7 allele is a potential risk factor for adult brain tumors in Taiwanese population.
  • The association of NAT2 polymorphisms with adult brain tumors has been unclear.
  • To investigate whether the NAT2 genotype is a risk factor of brain tumors, we determined the frequencies of three common polymorphisms in the NAT2 gene, NAT2*5 (T341C), NAT2*6 (G590A), and NAT2*7(G857A), in brain tumor patients and in age- and gender-matched control subjects (n = 27 in each group).
  • The odds ratio of NAT2*7 allele frequency was significantly higher in patients with brain tumor than in controls (odds ratio, 6.786; 95% confidence interval, 2.06-22.37; P = 0.003); in the mean time, NAT2*4/*7 genotype was significantly more common in the patient group than in controls (odds ratio, 6.19; 95% confidence interval, 1.68-22.79; P = 0.0039).
  • The tumors in the patients with NAT2*7 allele tended to be high-grade astrocytoma or glioblastoma multiforme (P = 0.016).
  • In conclusion, these data suggest that the presence of NAT2*7 allele might be a potential risk factor for the development of brain tumors in Taiwan.
  • [MeSH-major] Arylamine N-Acetyltransferase / genetics. Brain Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349284.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / NAT2 protein, human
  •  go-up   go-down


34. Brainer-Lima PT, Brainer-Lima AM, Brandt CT, Carneiro GS, Azevedo HC: [Intraoperative mapping of motor areas during brain tumor surgery: electrical stimulation patterns]. Arq Neuropsiquiatr; 2005 Mar;63(1):55-60
Hazardous Substances Data Bank. PROPOFOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraoperative mapping of motor areas during brain tumor surgery: electrical stimulation patterns].
  • [Transliterated title] Mapeamento da área motora durante a cirurgia de tumor intracraniano: fatores que podem modificar a intensidade da estimulação.
  • Brain mapping with direct electrical stimulation is usefull when the tumor is located near or has infiltrated the central lobe.
  • OBJECTIVE: To analyze the surgical findings with direct electrical stimulation of the cortex and white matter under general anesthesia during surgery for brain tumors related to the central lobe.
  • We analyzed surgical findings and details of brain mapping.
  • [MeSH-major] Brain Mapping. Brain Neoplasms / surgery. Craniotomy / methods. Electric Stimulation / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Anesthetics, Intravenous / administration & dosage. Child. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Monitoring, Intraoperative. Motor Cortex. Propofol / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15830066.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Anesthetics, Intravenous; YI7VU623SF / Propofol
  •  go-up   go-down


35. Brandes AA, Franceschi E: Neuro-oncology: Genetic variation in pediatric and adult brain tumors. Nat Rev Neurol; 2010 Dec;6(12):653-4
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuro-oncology: Genetic variation in pediatric and adult brain tumors.
  • Two new studies suggest that pediatric medulloblastomas and high-grade gliomas are genetically different from the same tumors in adults.
  • Age-dependent gene expression might affect tumor biology; therefore, therapies for adult medulloblastomas or gliomas might not produce the same clinical outcomes in pediatric patients, and vice versa.
  • [MeSH-major] Brain Neoplasms / genetics. Cerebellar Neoplasms / genetics. Gene Expression Profiling. Glioma / genetics. Medulloblastoma / genetics
  • [MeSH-minor] Adult. Child. Genetic Variation. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21131914.001).
  • [ISSN] 1759-4766
  • [Journal-full-title] Nature reviews. Neurology
  • [ISO-abbreviation] Nat Rev Neurol
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] England
  •  go-up   go-down


36. Rajaraman P, Hutchinson A, Rothman N, Black PM, Fine HA, Loeffler JS, Selker RG, Shapiro WR, Linet MS, Inskip PD: Oxidative response gene polymorphisms and risk of adult brain tumors. Neuro Oncol; 2008 Oct;10(5):709-15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxidative response gene polymorphisms and risk of adult brain tumors.
  • Oxidative stress is believed to play a key role in tumor formation.
  • Although this mechanism could be especially pertinent for brain tumors given the high oxygen consumption of the brain, very little has been published regarding brain tumor risk with respect to genes mediating oxidative stress.
  • Our results suggest that common variants in the SOD2, SOD3, and CAT genes may influence brain tumor risk.
  • [MeSH-major] Brain Neoplasms / genetics. Catalase / genetics. Oxidative Stress / genetics. Polymorphism, Single Nucleotide / genetics. Superoxide Dismutase / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Genetic Predisposition to Disease. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2006 Sep;27(9):1828-34 [16543247.001]
  • [Cites] Exp Toxicol Pathol. 2005 Jul;57 Suppl 1:161-9 [16092724.001]
  • [Cites] Cell Biochem Funct. 2006 Sep-Oct;24(5):455-60 [16142697.001]
  • [Cites] Haematologica. 2006 Sep;91(9):1222-7 [16956821.001]
  • [Cites] Cancer Causes Control. 2005 Dec;16(10):1225-34 [16215873.001]
  • [Cites] Am J Epidemiol. 2005 Nov 15;162(10):943-52 [16192345.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D617-21 [16381944.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2844-52 [16510607.001]
  • [Cites] Carcinogenesis. 2006 Apr;27(4):820-5 [16287877.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1217-22 [16775184.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1226-8 [16775186.001]
  • [Cites] J Neurochem. 2006 Jun;97(6):1634-58 [16805774.001]
  • [Cites] BMC Cancer. 2006;6:217 [16945136.001]
  • [Cites] J Thorac Oncol. 2006 Sep;1(7):648-53 [17409931.001]
  • [Cites] Int J Cancer. 2007 Jun 15;120(12):2739-43 [17290392.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1581-6 [17646272.001]
  • [Cites] Clin Chim Acta. 2000 Jun;296(1-2):203-12 [10807983.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6381-3 [11103801.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):79-86 [11150357.001]
  • [Cites] Arch Biochem Biophys. 2001 May 1;389(1):84-93 [11370676.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):276-85 [12671666.001]
  • [Cites] J Natl Cancer Inst. 2003 Jun 4;95(11):812-8 [12783936.001]
  • [Cites] Cancer Causes Control. 2003 Aug;14(6):513-8 [12948282.001]
  • [Cites] Carcinogenesis. 2004 Jun;25(6):973-8 [14729580.001]
  • [Cites] Gynecol Oncol. 2004 Jun;93(3):615-20 [15196853.001]
  • [Cites] J Urol. 2004 Aug;172(2):728-32 [15247771.001]
  • [Cites] Acta Neurol Scand. 1998 Sep;98(3):145-53 [9786609.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):602-6 [9973207.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2498-504 [15781667.001]
  • [Cites] Pharmacogenet Genomics. 2005 May;15(5):311-9 [15864132.001]
  • [Cites] Environ Health Perspect. 2005 Jul;113(7):909-13 [16002382.001]
  • [Cites] Nat Clin Pract Neurol. 2006 Sep;2(9):494-503; quiz 1 p following 516 [16932614.001]
  • (PMID = 18682580.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.11.1.6 / Catalase; EC 1.15.1.1 / SOD3 protein, human; EC 1.15.1.1 / Superoxide Dismutase; EC 1.15.1.1 / superoxide dismutase 2
  • [Other-IDs] NLM/ PMC2666247
  •  go-up   go-down


37. Hatch EE, Linet MS, Zhang J, Fine HA, Shapiro WR, Selker RG, Black PM, Inskip PD: Reproductive and hormonal factors and risk of brain tumors in adult females. Int J Cancer; 2005 May 1;114(5):797-805
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reproductive and hormonal factors and risk of brain tumors in adult females.
  • Causes of brain tumors are largely unknown, and there is an urgent need to identify possible risk factors.
  • Several observations point to a possible role of reproductive hormones, but few epidemiologic studies have examined whether reproductive factors, such as age at menarche and parity, are associated with brain tumor risk.
  • Research nurses interviewed patients regarding potential risk factors for brain tumors, including reproductive factors and hormone use.
  • Possibly owing to low statistical power, there were few noteworthy associations between meningioma and reproductive factors, other than a nonsignificant (p = 0.09) trend of increasing risk with increasing age at menopause.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Contraceptives, Oral / pharmacology. Female. Glioma / diagnosis. Glioma / etiology. Glioma / metabolism. Hormones / metabolism. Humans. Menarche. Meningioma / diagnosis. Meningioma / etiology. Meningioma / metabolism. Menopause. Middle Aged. Odds Ratio. Risk. Risk Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 Wiley-Liss, Inc.
  • (PMID = 15609304.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptives, Oral; 0 / Hormones
  •  go-up   go-down


38. Terry MB, Howe G, Pogoda JM, Zhang FF, Ahlbom A, Choi W, Giles GG, Little J, Lubin F, Menegoz F, Ryan P, Schlehofer B, Preston-Martin S: An international case-control study of adult diet and brain tumor risk: a histology-specific analysis by food group. Ann Epidemiol; 2009 Mar;19(3):161-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An international case-control study of adult diet and brain tumor risk: a histology-specific analysis by food group.
  • PURPOSE: Existing studies of diet and adult brain tumors have been limited by small numbers in histology-specific subgroups.
  • Dietary data from an international collaborative case-control study on adult brain tumors were used to evaluate associations between histology-specific risk and consumption of specific food groups.
  • Of the 1548 cases, 1185 were gliomas, 332 were meningiomas, and 31 were other tumor types.
  • CONCLUSIONS: Our study suggests that selected dietary food groups may be associated with adult gliomas and its subtypes but not meningiomas.

  • Genetic Alliance. consumer health - Brain Tumor, Adult.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2000 May 15;151(10):939-45 [10853631.001]
  • [Cites] Int J Cancer. 1992 Apr 22;51(1):20-7 [1563840.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(5):696-704 [11916553.001]
  • [Cites] Cancer Causes Control. 2002 Sep;13(7):647-55 [12296512.001]
  • [Cites] Cancer Causes Control. 2004 Feb;15(1):99-100 [15049327.001]
  • [Cites] J Natl Cancer Inst. 1980 Jul;65(1):67-73 [6930521.001]
  • [Cites] J Natl Cancer Inst. 1983 May;70(5):863-6 [6573530.001]
  • [Cites] IARC Sci Publ. 1984;(57):887-94 [6533073.001]
  • [Cites] Int J Cancer. 1993 Feb 20;53(4):561-5 [8436429.001]
  • [Cites] Int J Cancer. 1994 Nov 1;59(3):357-62 [7927941.001]
  • [Cites] Cancer Causes Control. 1997 Jan;8(1):3-4 [9051316.001]
  • [Cites] Cancer Causes Control. 1997 Jan;8(1):5-12 [9051317.001]
  • [Cites] Cancer Causes Control. 1997 Jan;8(1):13-24 [9051318.001]
  • [Cites] Am J Epidemiol. 1997 Nov 15;146(10):832-41 [9384204.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jul;7(7):635-8 [9681534.001]
  • [Cites] Int J Epidemiol. 1998 Aug;27(4):579-86 [9758110.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):20-3 [10077146.001]
  • [Cites] Am J Clin Nutr. 1999 Jun;69(6):1315S-1321S [10359232.001]
  • [Cites] Int J Cancer. 1999 Jul 19;82(2):155-60 [10389745.001]
  • [Cites] Int J Cancer. 2005 Jan 1;113(1):116-25 [15386358.001]
  • [Cites] Am J Clin Nutr. 2007 Mar;85(3):877-86 [17344512.001]
  • [Cites] Ann Epidemiol. 2009 Mar;19(3):148-60 [19216997.001]
  • [Cites] Biometrics. 1986 Mar;42(1):121-30 [3719049.001]
  • [Cites] Am J Epidemiol. 1986 Oct;124(4):595-602 [3752053.001]
  • [Cites] J Natl Cancer Inst. 1987 Apr;78(4):601-9 [3104645.001]
  • [Cites] IARC Sci Publ. 1989;(96):17-34 [2553598.001]
  • [Cites] IARC Sci Publ. 1991;(105):197-203 [1855850.001]
  • [Cites] Int J Epidemiol. 2001 Apr;30(2):317-9 [11369736.001]
  • (PMID = 19216998.001).
  • [ISSN] 1873-2585
  • [Journal-full-title] Annals of epidemiology
  • [ISO-abbreviation] Ann Epidemiol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K07 CA090685; United States / NCI NIH HHS / CA / T32 CA009529; United States / NCI NIH HHS / CA / K07CA90685
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS469516; NLM/ PMC3832293
  •  go-up   go-down


39. Chandana SR, Movva S, Arora M, Singh T: Primary brain tumors in adults. Am Fam Physician; 2008 May 15;77(10):1423-30
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary brain tumors in adults.
  • Primary malignant brain tumors account for 2 percent of all cancers in U.S. adults.
  • The most common malignant brain tumor is glioblastoma multiforme, and patients with this type of tumor have a poor prognosis.
  • Previous exposure to high-dose ionizing radiation is the only proven environmental risk factor for a brain tumor.
  • Primary brain tumors are classified based on their cellular origin and histologic appearance.
  • A tumor can be identified using brain imaging, and the diagnosis is confirmed with histopathology.
  • Any patient with chronic, persistent headache in association with protracted nausea, vomiting, seizures, change in headache pattern, neurologic symptoms, or positional worsening should be evaluated for a brain tumor.
  • A comprehensive neurosurgical evaluation is necessary to obtain tissue for diagnosis and for possible resection of the tumor.
  • Primary brain tumors rarely metastasize outside the central nervous system, and there is no standard staging method.
  • Surgical resection of the tumor is the mainstay of therapy.
  • Postoperative radiation and chemotherapy have improved survival in patients with high-grade brain tumors.
  • Recent developments in targeted chemotherapy provide novel treatment options for patients with tumor recurrence.
  • Primary care physicians play an important role in the perioperative and supportive treatment of patients with primary brain tumors, including palliative care and symptom control.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Glioma / diagnosis. Glioma / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy / methods. Female. Headache / etiology. Humans. Male. Medical History Taking / methods. Nausea / etiology. Radiotherapy, Adjuvant / methods. Seizures / etiology. Vomiting / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18533376.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


40. Ellert-Miklaszewska A, Grajkowska W, Gabrusiewicz K, Kaminska B, Konarska L: Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. Brain Res; 2007 Mar 16;1137(1):161-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors.
  • The efficacy of cannabinoids against high-grade glioma in animal models, mediated by two specific receptors, CB1 and CB2, raised promises for targeted treatment of the most frequent and malignant primary brain tumors.
  • Unlike the abundantly expressed CB1, the CB2 receptor shows a restricted distribution in normal brain.
  • Although brain tumors constitute the second most common malignancy in children and the prevalence of histological types of brain tumors vary significantly between the adult and pediatric populations, cannabinoid receptor expression in pediatric tumors remains unknown.
  • In the present study, we compared the expression of the CB2 receptor in paraffin-embedded sections from primary brain tumors of adult and pediatric patients.
  • Most glioblastomas expressed very high levels of CB2 receptors and the expression correlated with tumor grade.
  • Interestingly, some benign pediatric astrocytic tumors, such as subependymal giant cell astrocytoma (SEGA), which may occasionally cause mortality owing to progressive growth, also displayed high CB2 immunoreactivity.
  • The high levels of CB2 expression would predestine those tumors to be vulnerable to cannabinoid treatment.
  • In contrast, all examined cases of embryonal tumors (medulloblastoma and S-PNET), the most frequently diagnosed malignant brain tumors in childhood, showed no or trace CB2 immunoreactivity.
  • Our results suggest that the CB2 receptor expression depends primarily on the histopathological origin of the brain tumor cells and differentiation state, reflecting the tumor grade.
  • [MeSH-major] Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Receptor, Cannabinoid, CB2 / metabolism
  • [MeSH-minor] Adolescent. Adult. Age Factors. Astrocytoma / metabolism. Child. Glioblastoma / metabolism. Histocompatibility Antigens / metabolism. Humans. Immunohistochemistry. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17239827.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Histocompatibility Antigens; 0 / Receptor, Cannabinoid, CB2
  •  go-up   go-down


41. Ownsworth T, Hawkes A, Steginga S, Walker D, Shum D: A biopsychosocial perspective on adjustment and quality of life following brain tumor: a systematic evaluation of the literature. Disabil Rehabil; 2009;31(13):1038-55
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A biopsychosocial perspective on adjustment and quality of life following brain tumor: a systematic evaluation of the literature.
  • PURPOSE: To systematically evaluate the literature on quality of life and adjustment to brain tumor from a biopsychosocial perspective.
  • METHODS: On the basis of the cancer and brain injury literature, a biopsychosocial organisational framework was initially developed to support an evaluative review of the brain tumor literature.
  • Electronic searches of Medline, PsycINFO and CINAHL databases identified 48 empirical studies (1980-2007) that investigated factors associated with quality of life or the adjustment of adults with brain tumor.
  • In general, the relationships among pre-illness and brain tumor characteristics, psychosocial variables and quality of life were unclear and various gaps in the literature emerged.
  • CONCLUSIONS: Empirical findings within a biopsychosocial perspective may guide the development and delivery of support services for individuals with brain tumor; however, many important areas exist for future research.
  • [MeSH-major] Brain Neoplasms / rehabilitation. Quality of Life. Social Adjustment
  • [MeSH-minor] Adaptation, Psychological. Adult. Depression / epidemiology. Family Health. Humans. Incidence. Social Support

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19116809.001).
  • [ISSN] 0963-8288
  • [Journal-full-title] Disability and rehabilitation
  • [ISO-abbreviation] Disabil Rehabil
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 99
  •  go-up   go-down


42. Lynch JC, Emmerich JC, Kislanov S, Gouvêa F, Câmara L, Santos Silva SM, D'Ippolito MM: [Brain tumors and pregnancy]. Arq Neuropsiquiatr; 2007 Dec;65(4B):1211-5
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Brain tumors and pregnancy].
  • [Transliterated title] Tumor cerebral e gravidez.
  • BACKGROUND: Despite not being a common fact, the occurrence of brain tumors during pregnancy poses a risk to both the mother and infant.
  • AIM: To identify the best medical procedure to be followed for a pregnant patient harboring a brain tumor.
  • METHOD: The records of 6 patients with brain tumors, diagnosed during pregnancy were examined.
  • RESULTS: Several types of brain tumors have been associated with pregnancy, but the meningioma is, by far, the most frequent.
  • It seems that pregnancy aggravates the clinical course of intracranial tumors.
  • CONCLUSION: The best moment to recommend the craniotomy and the neurosurgical removal of the tumor will depend of the mothers neurological condition, the tumor histological type as well as the gestational age.
  • [MeSH-major] Brain Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis
  • [MeSH-minor] Adult. Craniotomy. Female. Humans. Magnetic Resonance Imaging. Pregnancy. Retrospective Studies

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18345432.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


43. Umesh S, Tandon A, Santosh V, Anandh B, Sampath S, Chandramouli BA, Sastry Kolluri VR: Clinical and immunohistochemical prognostic factors in adult glioblastoma patients. Clin Neuropathol; 2009 Sep-Oct;28(5):362-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and immunohistochemical prognostic factors in adult glioblastoma patients.
  • OBJECTIVE: Glioblastomas are the commonest and the most malignant of all adult brain tumors, characterized by genetic instability, intratumoral histopathological variability, and unpredictable clinical behavior.
  • The utility of tumor markers that reflect their underlying biology is becoming increasingly important with respect to patient prognostication and their potential role as molecular targets of therapy is being recognized.
  • MATERIALS AND METHODS: We evaluated 54 cases of adult supratentorial glioblastomas operated over a span of 1 year, with respect to clinical features such as age, Karnofsky performance score (KPS), extent of resection, adjuvant therapy, and immunohistochemical expression of p53, EGFR (Epidermal Growth Factor Receptor) and PTEN (Phosphatase and Tensin homolog).
  • [MeSH-major] Glioblastoma / diagnosis. Supratentorial Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. PTEN Phosphohydrolase / metabolism. Prognosis. Receptor, Epidermal Growth Factor / metabolism. Severity of Illness Index. Treatment Outcome. Tumor Suppressor Protein p53 / metabolism. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19788052.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


44. Evers P, Lee PP, DeMarco J, Agazaryan N, Sayre JW, Selch M, Pajonk F: Irradiation of the potential cancer stem cell niches in the adult brain improves progression-free survival of patients with malignant glioma. BMC Cancer; 2010 Jul 21;10:384
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irradiation of the potential cancer stem cell niches in the adult brain improves progression-free survival of patients with malignant glioma.
  • BACKGROUND: Glioblastoma is the most common brain tumor in adults.
  • The mechanisms leading to glioblastoma are not well understood but animal studies support that inactivation of tumor suppressor genes in neural stem cells (NSC) is required and sufficient to induce glial cancers.
  • This suggests that the NSC niches in the brain may harbor cancer stem cells (CSCs), Thus providing novel therapy targets.
  • METHODS: 55 adult patients with Grade 3 or Grade 4 glial cancer treated with radiotherapy at UCLA between February of 2003 and May of 2009 were included in this retrospective study.
  • CONCLUSIONS: Our study leads us to hypothesize that in glioma targeted radiotherapy of the stem cell niches in the adult brain could yield significant benefits over radiotherapy of the primary tumor mass alone and that damage caused by smaller fractions of radiation maybe less efficiently detected by the DNA repair mechanisms in CSCs.

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Brain Stem Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Biol. 1999 Nov;75(11):1341-8 [10597908.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Sep;135(9):1239-44 [19277712.001]
  • [Cites] Radiother Oncol. 2002 Sep;64(3):259-73 [12242114.001]
  • [Cites] J Comp Neurol. 2003 Apr 14;458(4):381-8 [12619072.001]
  • [Cites] Int J Cancer. 2003 May 20;105(1):33-40 [12672027.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Brain Res. 2004 Jan 23;996(2):213-26 [14697499.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(1):103-8 [1309203.001]
  • [Cites] Science. 1992 Mar 27;255(5052):1707-10 [1553558.001]
  • [Cites] J Neurosci. 1992 Nov;12(11):4565-74 [1432110.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11879-83 [8524867.001]
  • [Cites] Neurosurgery. 1998 Apr;42(4):709-20; discussion 720-3 [9574634.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Novartis Found Symp. 2005;265:66-80; discussion 82-97 [16050251.001]
  • [Cites] Cell Death Differ. 2006 Jul;13(7):1238-41 [16456578.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 20;98(24):1777-85 [17179479.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):978-85 [17467925.001]
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):45-56 [19111880.001]
  • [Cites] EMBO J. 2009 Jan 7;28(1):8-20 [19037256.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):608-11 [19092804.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):603-7 [19092805.001]
  • [Cites] Am J Clin Oncol. 2009 Feb;32(1):20-2 [19194118.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1275-9 [19188675.001]
  • [Cites] Lancet Oncol. 2009 May;10(5):459-66 [19269895.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2008;73:421-6 [19022744.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • (PMID = 20663133.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA137110; United States / NCI NIH HHS / CA / R01CA137110-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2918578
  •  go-up   go-down


45. Shinoura N, Takahashi M, Yamada R: Delineation of brain tumor margins using intraoperative sononavigation: implications for tumor resection. J Clin Ultrasound; 2006 May;34(4):177-83
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delineation of brain tumor margins using intraoperative sononavigation: implications for tumor resection.
  • PURPOSE: Sonography has been employed for real-time intraoperative delineation of tumor boundaries during resection of brain tumors.
  • However, the variably hyperechoic appearance of brain edema or gliosis surrounding the brain may interfere with accurate depiction of tumor margins.
  • The goal of the present study was to use sononavigation, which provides coregistration between real-time sonograms and MRI scans, to assess the accuracy of sonographic determination of tumor margins.
  • METHODS: Sononavigation was performed on 12 brain tumors (7 metastatic brain tumors, 2 meningiomas, 1 anaplastic oligodendroglioma, 1 anaplastic pilocytic astrocytoma, and 1 anaplastic astrocytoma).
  • Sonograms of tumor margins were categorized into 1 of 3 types: in type 1, the tumor margin was clearly visualized and corresponded to the margin of the enhanced lesion on MR scan in all areas; in type 2, the tumor margin was clearly seen in some areas but was obscure in others due to hyperechoic edema; and in type 3, the tumor margin was indistinguishable from surrounding tissues in all areas.
  • RESULTS: Three metastatic brain tumors and 1 meningioma were categorized as type 1.
  • Three metastatic brain tumors, 1 meningioma, and 1 anaplastic oligodendroglioma were categorized as type 2.
  • The anaplastic pilocytic astrocytoma, 1 metastatic brain tumor (which consisted mainly of necrotic tissue), and the anaplastic astrocytoma were categorized as type 3.
  • These data assist in determining whether the sonographic appearance of tumor margins is accurate and whether to rely on information from either sonography (type 1) or the sononavigation system when resecting tumor types 1, 2, and 3.
  • CONCLUSIONS: Sononavigation can help categorize the sonographic tumor margins into 3 different patterns, and this categorization can assist in determining which imaging modalities are needed to better delineate the tumor margins for subsequent resection.
  • [MeSH-major] Brain Neoplasms / surgery. Brain Neoplasms / ultrasonography. Neuronavigation / methods. Ultrasonography, Interventional / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Intraoperative Period. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley Periodicals, Inc.
  • (PMID = 16615048.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


46. Tanaka A: Imaging diagnosis and fundamental knowledge of common brain tumors in adults. Radiat Med; 2006 Jul;24(6):482-92
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging diagnosis and fundamental knowledge of common brain tumors in adults.
  • The most common primary brain tumors in Japanese adults are meningiomas, gliomas, pituitary adenomas, and schwannomas, which together account for 84.0% of all primary brain tumors.
  • The typical imaging findings of these tumors are well known by radiologists; therefore, the clinical and pathological issues, including terminology, genetics, and relation to hormones are discussed in this article.
  • Other diseases important for the differential diagnoses are also mentioned.
  • The molecular genetic analysis of brain tumors has recently become important.
  • For instance, genetic analysis is important for differentiating oligodendroglial tumors from astrocytic tumors, and the gene mutation predicts response to chemotherapy for anaplastic oligodendrogliomas.
  • Background factors such as hormones, history of cranial irradiation, and medications influence oncogenesis, tumor growth, and tumor appearances as seen by imaging modalities.
  • Such conditions should be carefully distinguished from neoplasms.
  • [MeSH-major] Brain Neoplasms / diagnosis. Magnetic Resonance Imaging. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Glioma / diagnosis. Humans. Image Processing, Computer-Assisted. Japan / epidemiology. Meningioma / diagnosis. Neurilemmoma / diagnosis. Pituitary Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16958433.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 31
  •  go-up   go-down


47. Zhang JG, Kruse CA, Driggers L, Hoa N, Wisoff J, Allen JC, Zagzag D, Newcomb EW, Jadus MR: Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy. J Neurooncol; 2008 May;88(1):65-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy.
  • OBJECTIVES: We evaluated and compared tumor antigen precursor protein (TAPP) profiles in adult and pediatric brain tumors of 31 genes related to tumor associated antigens (TAA) for possible use in immunotherapy.
  • Antigens were selected based on their potential to stimulate T cell responses against tumors of neuroectodermal origin.
  • METHODS: Thirty-seven brain tumor specimens from 11 adult and 26 pediatric patients were analyzed by quantitative real-time PCR for the relative expression of 31 TAPP mRNAs.
  • The age range of adults (4F:7M) was 27-77 years (median 51.5 +/- 14.5 years) and for pediatrics (12F:14M) was 0.9-19 years (median 8.3 +/- 5.5 years).
  • RESULTS: The adult gliomas expressed 94% (29 of 31) of the TAPP mRNAs evaluated compared with pediatric brain tumors that expressed 55-74% of the TAPP mRNAs, dependent on tumor histological subtype.
  • (1) equal expression among adult and pediatric cases, (2) greater expression in adult than pediatric cases, (3) expression restricted to adult GBM and (4) a random distribution.
  • The pediatric brain tumors lacked expression of some genes associated with engendering tumor survival, such as hTert and Survivin.
  • CONCLUSIONS: The potential TAA targets identified from the TAPP profiles of 31 genes associated with adult and pediatric brain tumors may help investigators select specific target antigens for developing dendritic cell- or peptide-based vaccines or T cell-based immunotherapeutic approaches against brain tumors.

  • Genetic Alliance. consumer health - Brain Tumor, Adult.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4364-8 [12154041.001]
  • [Cites] Cancer Immunol Immunother. 2001 Sep;50(7):337-44 [11676393.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1077-83 [12569609.001]
  • [Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):13-20 [12952282.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4973-9 [15256471.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1656-62 [15477864.001]
  • [Cites] J Cell Biol. 1989 Dec;109(6 Pt 1):2575-87 [2687284.001]
  • [Cites] Hum Gene Ther. 1995 May;6(5):591-601 [7578396.001]
  • [Cites] Cancer Immunol Immunother. 1997 Oct;45(2):77-87 [9390198.001]
  • [Cites] Lancet. 1998 Mar 21;351(9106):882-3 [9525374.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):42-51 [9647171.001]
  • [Cites] J Biol Chem. 1999 Jan 15;274(3):1359-65 [9880507.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):359-65 [15655550.001]
  • [Cites] Neuro Oncol. 2005 Jul;7(3):225-35 [16053697.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5515-25 [16061868.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):342-63 [16389946.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):194-202 [16492905.001]
  • [Cites] Oncogene. 2006 May 4;25(19):2818-26 [16314830.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jul;47(1):4-13 [16534789.001]
  • [Cites] Int J Oncol. 2006 Jun;28(6):1555-60 [16685456.001]
  • [Cites] Neurosurg Focus. 2000;9(6):e9 [16817692.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Sep;65(9):905-13 [16957584.001]
  • [Cites] Cancer Gene Ther. 2006 Dec;13(12):1052-60 [16826191.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):988-99; discussioin 999-1000 [17143233.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):139-48 [17004103.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):566-75 [17255279.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):4960-3 [17785545.001]
  • [Cites] Immunology. 2007 Dec;122(4):615-22 [17645496.001]
  • [Cites] Oncogene. 2000 Feb 3;19(5):617-23 [10698506.001]
  • [Cites] J Neurooncol. 1999;45(2):141-57 [10778730.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2209-18 [10873070.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):152-62 [11285553.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2851-5 [12231526.001]
  • (PMID = 18259692.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA121258; United States / NINDS NIH HHS / NS / NS 046463; United States / NCI NIH HHS / CA / CA 121258; United States / NINDS NIH HHS / NS / R21 NS057829; United States / NINDS NIH HHS / NS / NS 054093; United States / NINDS NIH HHS / NS / NS 056300; United States / NINDS NIH HHS / NS / R21 NS056300; United States / NINDS NIH HHS / NS / R21 NS046463; United States / NINDS NIH HHS / NS / NS 057829
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Protein Precursors; 0 / RNA, Messenger
  • [Other-IDs] NLM/ NIHMS572988; NLM/ PMC4005736
  •  go-up   go-down


48. Rajaraman P, Wang SS, Rothman N, Brown MM, Black PM, Fine HA, Loeffler JS, Selker RG, Shapiro WR, Chanock SJ, Inskip PD: Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev; 2007 Aug;16(8):1655-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults.
  • Despite the potential importance of the cell cycle and apoptosis pathways in brain tumor etiology, little has been published regarding brain tumor risk associated with common gene variants in these pathways.
  • Our results suggest that common variants in the CASP8, CCND1, CCNH, and MDM2 genes may influence brain tumor risk.
  • [MeSH-major] Apoptosis / genetics. Brain Neoplasms / genetics. Genes, cdc. Polymorphism, Single Nucleotide / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Caspase 8 / genetics. Checkpoint Kinase 2. Cyclin D. Cyclin H. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Cyclins / genetics. Exons / genetics. Female. Genes, Tumor Suppressor. Genes, p16. Genes, p53 / genetics. Genetic Variation / genetics. Glioma / genetics. Haplotypes. Humans. Male. Meningioma / genetics. Middle Aged. Neuroma, Acoustic / genetics. PTEN Phosphohydrolase / genetics. Protein Kinases / genetics. Protein-Serine-Threonine Kinases / genetics. Proto-Oncogene Proteins c-mdm2 / genetics. Risk Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17684142.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCNH protein, human; 0 / CDKN1A protein, human; 0 / Cyclin D; 0 / Cyclin H; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; EC 2.7.- / Protein Kinases; EC 2.7.1.11 / Checkpoint Kinase 2; EC 2.7.11.1 / CHEK2 protein, human; EC 2.7.11.1 / Checkpoint kinase 1; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 8; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


49. Rajaraman P, Schwartz BS, Rothman N, Yeager M, Fine HA, Shapiro WR, Selker RG, Black PM, Inskip PD: Delta-aminolevulinic acid dehydratase polymorphism and risk of brain tumors in adults. Environ Health Perspect; 2005 Sep;113(9):1209-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delta-aminolevulinic acid dehydratase polymorphism and risk of brain tumors in adults.
  • The enzyme delta-aminolevulinic acid dehydratase (ALAD), which catalyzes the second step of heme synthesis, can be inhibited by several chemicals, including lead, a potential risk factor for brain tumors, particularly meningioma.
  • In this study we examined whether the ALAD G177C polymorphism in the gene coding for ALAD is associated with risk of intracranial tumors of the brain and nervous system.
  • We use data from a case-control study with 782 incident brain tumor cases and 799 controls frequency matched on hospital, age, sex, race/ethnicity, and residential proximity to the hospital.
  • [MeSH-major] Brain Neoplasms / genetics. Genetic Predisposition to Disease. Meningioma / genetics. Porphobilinogen Synthase / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Arizona. Case-Control Studies. Environmental Exposure. Female. Humans. Male. Massachusetts. Middle Aged. Pennsylvania. Polymorphism, Genetic. Sex Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Hum Genet. 1981 Jul;45(Pt 3):223-9 [7305279.001]
  • [Cites] Am J Ind Med. 2004 May;45(5):395-407 [15095422.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440 [3482203.001]
  • [Cites] Environ Res. 1991 Dec;56(2):109-19 [1769358.001]
  • [Cites] Methods Enzymol. 1996;272:199-210 [8791778.001]
  • [Cites] Pharmacol Toxicol. 1997 Oct;81(4):153-8 [9353844.001]
  • [Cites] Environ Res. 1998 Apr;77(1):49-61 [9593628.001]
  • [Cites] Environ Health Perspect. 1998 Apr;106(4):213-6 [9495797.001]
  • [Cites] Am J Ind Med. 1999 Jul;36(1):70-4 [10361589.001]
  • [Cites] Int J Cancer. 1999 Oct 29;83(3):299-304 [10495419.001]
  • [Cites] J Occup Environ Med. 2000 Feb;42(2):151-5 [10693075.001]
  • [Cites] Am J Ind Med. 2000 Sep;38(3):295-9 [10940967.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):79-86 [11150357.001]
  • [Cites] Environ Res. 2001 Mar;85(3):185-90 [11237505.001]
  • [Cites] Am J Epidemiol. 2001 Jul 1;154(1):1-13 [11427399.001]
  • [Cites] Am J Ind Med. 2002 Sep;42(3):214-27 [12210690.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] Tohoku J Exp Med. 2002 Feb;196(2):53-64 [12498316.001]
  • [Cites] Mutat Res. 2003 Dec 10;533(1-2):121-33 [14643416.001]
  • [Cites] Int Arch Occup Environ Health. 1986;58(3):245-7 [3770964.001]
  • (PMID = 16140629.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 4.2.1.24 / Porphobilinogen Synthase
  • [Other-IDs] NLM/ PMC1280403
  •  go-up   go-down


50. Panagiotakos G, Tabar V: Brain tumor stem cells. Curr Neurol Neurosci Rep; 2007 May;7(3):215-20
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumor stem cells.
  • The concept of brain tumor stem cells is gaining increased recognition in neuro-oncology.
  • Until recently, the paradigm of a tumor-initiating stem cell was confined to hematopoietic malignancies where the hierarchical lineages of stem progenitor cells are well established.
  • The demonstration of persistent stem cells and cycling progenitors in the adult brain, coupled with the expansion of the cancer stem cell concept to solid tumors, has led to the exploration of "stemness" within gliomas.
  • Emerging data are highly suggestive of the subsistence of transformed multipotential cells within a glioma, with a subfraction of cells exhibiting increased efficiency at tumor initiation.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplastic Stem Cells / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488587.001).
  • [ISSN] 1528-4042
  • [Journal-full-title] Current neurology and neuroscience reports
  • [ISO-abbreviation] Curr Neurol Neurosci Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


51. Yilmaz N, Dulger H, Kiymaz N, Yilmaz C, Bayram I, Ragip B, Oğer M: Lipid peroxidation in patients with brain tumor. Int J Neurosci; 2006 Aug;116(8):937-43
Hazardous Substances Data Bank. MALONALDEHYDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipid peroxidation in patients with brain tumor.
  • Molecular and genetic signatures may predict brain tumor behavior and may soon guide tumor classification, diagnosis, and tumor-specific treatment strategies.
  • This article explored the state of FORs and antioxidant system in patients with cerebral tumor.
  • The serum concentrations of malondialdehyde (MDA), catalase, and glutathione peroxidase (GSH-Px) enzyme activities were measured in the serum of 35 patients with cerebral tumors (21 glioma, 14 meningioma) and 11 controls.
  • Mean serum MDA levels, catalase, and GSH-Px enzyme activities were significantly higher for both glial and meningiomal tumor cases when compared to controls (p < .05).
  • In conclusion, lipid peroxidation and antioxidant enzymes as assessed by MDA, catalase, and GSH-Px were increased in patients with brain tumors, for this respect there is no difference between gliomas and meningiomas.
  • [MeSH-major] Brain Neoplasms / blood. Lipid Peroxidation / physiology
  • [MeSH-minor] Adolescent. Adult. Aged. Analysis of Variance. Catalase / blood. Child. Child, Preschool. Female. Glutathione Peroxidase / blood. Humans. Male. Malondialdehyde / blood. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861159.001).
  • [ISSN] 0020-7454
  • [Journal-full-title] The International journal of neuroscience
  • [ISO-abbreviation] Int. J. Neurosci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 4Y8F71G49Q / Malondialdehyde; EC 1.11.1.6 / Catalase; EC 1.11.1.9 / Glutathione Peroxidase
  •  go-up   go-down


52. Carlson-Green B: Brain tumor survivors speak out. J Pediatr Oncol Nurs; 2009 Sep-Oct;26(5):266-79
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumor survivors speak out.
  • Although progress has been made in the treatment of childhood brain tumors,work remains to understand the complexities of disease, treatment, and contextual factors that underlie individual differences in outcome.
  • A combination of both an idiographic approach (incorporating observations made by adult survivors of childhood brain tumors) and a nomothetic approach (reviewing the literature for brain tumor survivors as well as childhood cancer survivors) is presented.
  • Guidelines to assist health care professionals working with childhood brain tumor survivors are offered with the goal of improving psychosocial and neurocognitive outcomes in this population.
  • [MeSH-major] Brain Neoplasms / therapy. Survivors
  • [MeSH-minor] Adaptation, Psychological. Adult. Child. Cognition. Emotions. Employment. Humans. Insurance, Health. Interpersonal Relations. Sexuality

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19837957.001).
  • [ISSN] 1043-4542
  • [Journal-full-title] Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses
  • [ISO-abbreviation] J Pediatr Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Palm T, Schwamborn JC: Brain tumor stem cells. Biol Chem; 2010 Jun;391(6):607-17
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumor stem cells.
  • Since the end of the 'no-new-neuron' theory, emerging evidence from multiple studies has supported the existence of stem cells in neurogenic areas of the adult brain.
  • Along with this discovery, neural stem cells became candidate cells being at the origin of brain tumors.
  • In fact, it has been demonstrated that molecular mechanisms controlling self-renewal and differentiation are shared between brain tumor stem cells and neural stem cells and that corruption of genes implicated in these pathways can direct tumor growth.
  • Such therapeutic models underline the importance to study the cellular mechanisms implicated in fate decisions of neural stem cells and the oncogenic derivation of adult brain cells.
  • In this review, we discuss the putative origins of brain tumor stem cells and their possible implications on future therapies.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplastic Stem Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20370314.001).
  • [ISSN] 1437-4315
  • [Journal-full-title] Biological chemistry
  • [ISO-abbreviation] Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 107
  •  go-up   go-down


54. Keir ST, Farland MM, Lipp ES, Friedman HS: Distress persists in long-term brain tumor survivors with glioblastoma multiforme. J Cancer Surviv; 2008 Dec;2(4):269-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distress persists in long-term brain tumor survivors with glioblastoma multiforme.
  • INTRODUCTION: Glioblastoma multiforme (GBM) is the most common and aggressive type of primary brain tumor.
  • RESULTS: Eight-three brain tumor patients participated in this study.
  • CONCLUSIONS: This study indicates that LTS of GBM report experiencing distress at similar levels to other brain tumor patients.
  • [MeSH-major] Anxiety Disorders / epidemiology. Brain Neoplasms / psychology. Glioblastoma / psychology. Survivors
  • [MeSH-minor] Adult. Aged. Fatigue / epidemiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prevalence. Research Design


55. Maschio M, Dinapoli L, Zarabla A, Pompili A, Carapella CM, Pace A, Giannarelli D, Occhipinti E, Jandolo B: Outcome and tolerability of topiramate in brain tumor associated epilepsy. J Neurooncol; 2008 Jan;86(1):61-70
Hazardous Substances Data Bank. TOPIRAMATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and tolerability of topiramate in brain tumor associated epilepsy.
  • Epilepsy in brain tumor patients is often refractory to pharmacological treatments and can complicate the therapeutic management of these patients.
  • The aim of this study was to investigate the efficacy and tolerability of topiramate (TPM) in brain tumor associated epilepsy.
  • We studied 47 patients with brain tumors and epilepsy.
  • In the group of patients who had been in therapy with other AEDs prior to entering the study (n = 33), 19 patients had side effects (57.6%).
  • Tumor-related seizures are difficult to control with AEDs; the precise reasons for this difficulty are not yet clear.
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / complications. Female. Follow-Up Studies. Humans. Male. Middle Aged. Outcome Assessment (Health Care). Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17598071.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anticonvulsants; 0H73WJJ391 / topiramate; 30237-26-4 / Fructose
  •  go-up   go-down


56. Matsuo K, Yamada K, Nakajima K, Nakagawa M: Neuro-Behçet disease mimicking brain tumor. AJNR Am J Neuroradiol; 2005 Mar;26(3):650-3
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuro-Behçet disease mimicking brain tumor.
  • We report a case of neuro-Behcet disease mimicked a brain tumor.
  • This case was initially considered as a brain tumor from mass lesion with edema at left basal ganglia on radiologic images.
  • [MeSH-major] Behcet Syndrome / diagnosis. Brain Neoplasms / diagnosis. Nervous System Diseases / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Drug Therapy, Combination. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Methylprednisolone / therapeutic use. Prednisolone / therapeutic use


57. Feuerstein M, Hansen JA, Calvio LC, Johnson L, Ronquillo JG: Work productivity in brain tumor survivors. J Occup Environ Med; 2007 Jul;49(7):803-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Work productivity in brain tumor survivors.
  • OBJECTIVE: To determine the association of symptom burden to work limitation among working survivors of malignant brain tumors.
  • METHODS: Working adults with malignant brain tumors (n = 95) and a non-cancer comparison (n = 131) group completed a web-based questionnaire.
  • Measures of demographics, tumor type and treatment, fatigue, emotional distress, cognitive limitations, and factors that can positively impact work, including health behaviors and problem solving, were obtained.
  • RESULTS: Survivors of malignant brain tumors reported higher levels of work limitations and time off from work than the non-cancer group.
  • Higher levels of symptom burden, lower levels of health behaviors, and more negative problem solving orientation were characteristic of the brain tumor survivor group.
  • These variables were not differentially associated with work limitations among brain cancer survivors or the comparison group.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17622854.001).
  • [ISSN] 1076-2752
  • [Journal-full-title] Journal of occupational and environmental medicine
  • [ISO-abbreviation] J. Occup. Environ. Med.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


58. Appenzeller S, de Castro R, Queiroz Lde S, Madegan L, Soledade C, Zanardi Vde A, Nucci A, Cendes F, Fernandes SR: Brain tumor-like lesion in Behçet disease. Rheumatol Int; 2006 Apr;26(6):577-80
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumor-like lesion in Behçet disease.
  • Stereotactic brain biopsy disclosed gliosis with no signs of malignancy.
  • After 8 weeks she had improved and a new MRI showed disappearance of the tumor-like lesion.
  • The differential diagnosis, especially with central nervous system tumor is emphasized.
  • [MeSH-major] Behcet Syndrome / diagnosis. Brain Diseases / diagnosis
  • [MeSH-minor] Adult. Brain Neoplasms / diagnosis. Central Nervous System Neoplasms / diagnosis. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Drug Therapy, Combination. Female. Follow-Up Studies. Headache / physiopathology. Humans. Immunosuppressive Agents / administration & dosage. Injections, Intravenous. Magnetic Resonance Imaging. Mesencephalon / pathology. Methylprednisolone / administration & dosage. Pulse Therapy, Drug. Stereotaxic Techniques. Thalamus / pathology. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Behcet's Disease.
  • MedlinePlus Health Information. consumer health - Behcet's Syndrome.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16328418.001).
  • [ISSN] 0172-8172
  • [Journal-full-title] Rheumatology international
  • [ISO-abbreviation] Rheumatol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


59. Nicoletti F, Arcella A, Iacovelli L, Battaglia G, Giangaspero F, Melchiorri D: Metabotropic glutamate receptors: new targets for the control of tumor growth? Trends Pharmacol Sci; 2007 May;28(5):206-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabotropic glutamate receptors: new targets for the control of tumor growth?
  • Cancer stem cells are currently a target for the treatment of malignant tumors.
  • Transformed neural stem-progenitor cells of the brain subventricular zone and the external granular layer of the cerebellum are the putative cells of origin of malignant gliomas and medulloblastomas, which are the most frequent malignant brain tumors in adults and children, respectively.
  • At least two receptor subtypes - mGlu(3) and mGlu(4) receptors - control the proliferation of brain tumor cells, whereas mGlu(1) receptors have been implicated in the development of melanomas.
  • We believe that individual mGlu receptor subtypes represent new potential targets for the treatment of several malignant tumors, including brain tumors.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Brain Neoplasms / drug therapy. Drug Delivery Systems. Receptors, Metabotropic Glutamate / drug effects
  • [MeSH-minor] Adult. Animals. Cell Proliferation. Child. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / physiopathology. Drug Resistance, Neoplasm. Gene Expression. Humans. Ligands. Melanoma / drug therapy. Melanoma / physiopathology. Neoplastic Stem Cells / drug effects. Skin Neoplasms / drug therapy. Skin Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17433452.001).
  • [ISSN] 0165-6147
  • [Journal-full-title] Trends in pharmacological sciences
  • [ISO-abbreviation] Trends Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ligands; 0 / Receptors, Metabotropic Glutamate
  •  go-up   go-down


60. Nern C, Sommerlad D, Acker T, Plate KH: Brain tumor stem cells. Recent Results Cancer Res; 2009;171:241-59
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumor stem cells.
  • The dogma that solid tumors are composed of tumor cells that all share the same ability to produce proliferating daughter cells has been challenged in recent years.
  • There is growing evidence that many adult tissues contain a set of tissue stem cells, which might undergo malignant transformation while retaining their stem cell characteristics.
  • Brain tumors such as medulloblastomas or glioblastomas often contain areas of divergent differentiation, which raises the intriguing question of whether these tumors could derive from neural stem cells (NSCs).This chapter reviews the current knowledge of NSCs and relates them to brain tumor pathology.
  • Current therapy protocols for malignant brain tumors are targeted toward the reduction of bulk tumor mass.
  • The concept of brain-tumor stem cells could provide new insights for future therapies, if the capacity for self-renewal of tumor cells and growth of the tumor mass would reside within a small subset of cancer cells.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplastic Stem Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19322548.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides
  • [Number-of-references] 117
  •  go-up   go-down


61. Huisman TA: Tumor-like lesions of the brain. Cancer Imaging; 2009;9 Spec No A:S10-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-like lesions of the brain.
  • Differentiation between tumors and tumor-like lesions of the central nervous system is essential for planning adequate treatment and for estimating outcome and future prognosis.
  • The radiologist should be aware of all non-neoplastic pathologies and diseases that may mimic tumors.
  • In the current review, frequent tumor-like lesions are discussed.
  • [MeSH-major] Brain Diseases / diagnosis. Brain Neoplasms / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Brain Abscess / diagnosis. Brain Abscess / pathology. Brain Diseases, Metabolic / diagnosis. Brain Diseases, Metabolic / pathology. Brain Ischemia / diagnosis. Brain Ischemia / pathology. Cerebral Hemorrhage / diagnosis. Cerebral Hemorrhage / pathology. Child. Demyelinating Diseases / diagnosis. Demyelinating Diseases / pathology. Diagnosis, Differential. Humans. Neurocutaneous Syndromes / diagnosis. Neurocutaneous Syndromes / pathology. Vasculitis / diagnosis. Vasculitis / pathology

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Neurol. 2002 Jan;26(1):18-25 [11814730.001]
  • [Cites] Arch Neurol. 2008 Dec;65(12):1629-33 [19064750.001]
  • [Cites] Ann Rheum Dis. 2008 Dec;67(12):1732-5 [18625623.001]
  • [Cites] Kaohsiung J Med Sci. 2008 Apr;24(4):218-22 [18424360.001]
  • (PMID = 19965288.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 4
  • [Other-IDs] NLM/ PMC2797474
  •  go-up   go-down


62. Senturk S, Oguz KK, Soylemezoglu F, Inci S: Cerebral alveolar echinoccosis mimicking primary brain tumor. AJNR Am J Neuroradiol; 2006 Feb;27(2):420-2
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral alveolar echinoccosis mimicking primary brain tumor.
  • We present a case of cerebral infestation by Echinococcosis multilocularis mimicking an infiltrative primary brain tumor.
  • [MeSH-major] Brain Neoplasms / diagnosis. Central Nervous System Parasitic Infections / diagnosis. Echinococcosis / diagnosis. Echinococcus multilocularis. Magnetic Resonance Imaging. Thalamic Diseases / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Animals. Brain Edema / diagnosis. Calcinosis / diagnosis. Diagnosis, Differential. Echinococcosis, Hepatic / diagnosis. Female. Humans. Thalamus / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484422.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Holland H, Koschny R, Krupp W, Meixensberger J, Bauer M, Schober R, Kirsten H, Ganten TM, Ahnert P: Cytogenetic and molecular biological characterization of an adult medulloblastoma. Cancer Genet Cytogenet; 2007 Oct 15;178(2):104-13
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic and molecular biological characterization of an adult medulloblastoma.
  • Medulloblastoma is a malignant invasive embryonal tumor, occurring in children mainly.
  • It is rare in adults (<1% of adult brain tumors), and so comprehensive cytogenetic and molecular biological data on adult medulloblastomas are very limited.
  • We performed comprehensive cytogenetic analyses of an adult medulloblastoma, WHO grade IV, using trypsin-Giemsa staining (GTG-banding), multicolor fluorescence in situ hybridization (M-FISH), and locus-specific FISH, complemented by molecular karyotyping using high-density single nucleotide polymorphism (SNP) arrays.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Medulloblastoma / genetics
  • [MeSH-minor] Adult. Child. Chromosome Aberrations. Chromosome Banding. Female. Flow Cytometry. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Matrix Metalloproteinase 2 / genetics. Phosphopyruvate Hydratase / genetics. Polymorphism, Single Nucleotide. Synaptophysin / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954265.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Synaptophysin; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


64. Merchant TE, Pollack IF, Loeffler JS: Brain tumors across the age spectrum: biology, therapy, and late effects. Semin Radiat Oncol; 2010 Jan;20(1):58-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumors across the age spectrum: biology, therapy, and late effects.
  • The clinical difference between brain tumors in adults and children is striking.
  • Compared with adults, pediatric tumor types (mostly glial and neuronal) are more sensitive to adjuvant irradiation and chemotherapy.
  • Pediatric tumors more often require craniospinal irradiation based on their propensity to disseminate within the neuraxis.
  • In this review of glioma, ependymoma, and medulloblastoma, we highlight the differences between adults and children, including the higher incidence of spinal cord ependymoma and supratentorial high-grade glioma in the adult and a higher incidence of medulloblastoma in the child.
  • In some settings, the radiation oncologist should suggest further surgery or additional adjuvant therapy in an effort to optimize local tumor control.
  • An effort is underway to better characterize adult and pediatric brain tumors biologically with an emphasis on improving our understanding of tumor genesis, malignant transformation, and some of the similarities and differences between tumor types and their response to conventional therapy.
  • [MeSH-major] Brain Neoplasms / epidemiology. Brain Neoplasms / therapy. Glioma / epidemiology. Glioma / therapy. Radiotherapy / adverse effects
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Child. Child, Preschool. Combined Modality Therapy / methods. Disease Progression. Ependymoma / epidemiology. Ependymoma / therapy. Humans. Incidence. Infant. Infant, Newborn. Medulloblastoma / epidemiology. Medulloblastoma / therapy. Radiation Injuries. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2009 Mar;10(3):258-66 [19274783.001]
  • [Cites] Brain Pathol. 2009 Jan;19(1):81-90 [18452568.001]
  • [Cites] J Pathol. 2009 Jun;218(2):172-81 [19373855.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3):623-31; discussion 631-2 [10981749.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):287-95 [10661334.001]
  • [Cites] J Neurooncol. 2009 Jul;93(3):343-8 [19142584.001]
  • [Cites] Histopathology. 2000 Nov;37(5):437-44 [11119125.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):52-7 [12007941.001]
  • [Cites] J Pathol. 2002 Jun;197(2):238-44 [12015749.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):855-60 [12377339.001]
  • [Cites] Neurosurgery. 2003 Sep;53(3):544-53; discussion 554-5 [12943571.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):755-61 [14529781.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):978-86 [15758008.001]
  • [Cites] J Neurosurg. 2005 Apr;102(4):629-36 [15871504.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8853-62 [16314645.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):313-9 [16200343.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2070-9 [16609018.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4202-8 [16943538.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):682-9 [17308273.001]
  • [Cites] Brain Pathol. 2007 Apr;17(2):146-50 [17388945.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1196-208 [17401009.001]
  • [Cites] Brain. 2007 May;130(Pt 5):1338-49 [17449478.001]
  • [Cites] Neurochirurgie. 2007 Jun;53(2-3 Pt 1):66-75 [17475290.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):782-7 [17892918.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3691-7 [19581535.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3598-604 [19581536.001]
  • [Cites] J Neurooncol. 2009 Sep;94(3):391-8 [19330288.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):496-503 [19464817.001]
  • [Cites] Childs Nerv Syst. 2009 Oct;25(10):1261-8 [19373477.001]
  • [Cites] Cancer. 2008 Apr 1;112(7):1568-74 [18278809.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]
  • [Cites] Arch Pathol Lab Med. 2008 Jun;132(6):993-1007 [18517285.001]
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):3965-70 [18711186.001]
  • [Cites] Curr Opin Neurol. 2008 Dec;21(6):754-61 [18989122.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1627-36 [19255330.001]
  • (PMID = 19959032.001).
  • [ISSN] 1532-9461
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  • [Other-IDs] NLM/ NIHMS425593; NLM/ PMC3529408
  •  go-up   go-down


65. Douw L, van Dellen E, de Groot M, Heimans JJ, Klein M, Stam CJ, Reijneveld JC: Epilepsy is related to theta band brain connectivity and network topology in brain tumor patients. BMC Neurosci; 2010;11:103
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epilepsy is related to theta band brain connectivity and network topology in brain tumor patients.
  • BACKGROUND: Both epilepsy patients and brain tumor patients show altered functional connectivity and less optimal brain network topology when compared to healthy controls, particularly in the theta band.
  • Furthermore, the duration and characteristics of epilepsy may also influence functional interactions in brain networks.
  • However, the specific features of connectivity and networks in tumor-related epilepsy have not been investigated yet.
  • Furthermore, higher number of seizures was related to a less optimal, more random brain network topology.
  • Other factors were not significantly related to functional connectivity or network topology.
  • CONCLUSIONS: These results indicate that (pathologically) increased theta band connectivity is related to a higher number of epileptic seizures in brain tumor patients, suggesting that theta band connectivity changes are a hallmark of tumor-related epilepsy.
  • Furthermore, a more random brain network topology is related to greater vulnerability to seizures.
  • Thus, functional connectivity and brain network architecture may prove to be important parameters of tumor-related epilepsy.
  • [MeSH-major] Brain Neoplasms / complications. Brain Neoplasms / physiopathology. Epilepsy / epidemiology. Epilepsy / physiopathology. Neural Pathways / physiopathology. Theta Rhythm
  • [MeSH-minor] Adult. Aged. Algorithms. Anticonvulsants / therapeutic use. Electroencephalography. Female. Humans. Magnetoencephalography. Male. Middle Aged. Nerve Net / physiopathology. Neurosurgical Procedures

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 2006 Feb 8;26(6):1669-72 [16467513.001]
  • [Cites] Neuroimage. 2010 Sep;52(3):1059-69 [19819337.001]
  • [Cites] Clin Neurophysiol. 2006 Sep;117(9):2039-49 [16859985.001]
  • [Cites] Neuroimage. 2006 Sep;32(3):1335-44 [16815039.001]
  • [Cites] J Neurooncol. 2006 Dec;80(3):313-32 [16807780.001]
  • [Cites] Brain. 2007 Jan;130(Pt 1):65-77 [17082199.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19219-20 [17159140.001]
  • [Cites] Clin Neurophysiol. 2007 Apr;118(4):918-27 [17314065.001]
  • [Cites] Cereb Cortex. 2007 Oct;17(10):2407-19 [17204824.001]
  • [Cites] Clin Neurophysiol. 2007 Nov;118(11):2317-31 [17900977.001]
  • [Cites] Hum Brain Mapp. 2007 Nov;28(11):1178-93 [17266107.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6179-84 [18375756.001]
  • [Cites] PLoS One. 2008;3(4):e0002051 [18446219.001]
  • [Cites] Epilepsy Res. 2008 May;79(2-3):173-86 [18359200.001]
  • [Cites] Neuroimage. 2008 Aug 1;42(1):1-9 [18511300.001]
  • [Cites] Science. 2008 Jul 4;321(5885):53-7 [18599766.001]
  • [Cites] Exp Neurol. 2008 Aug;212(2):285-90 [18534578.001]
  • [Cites] Neuro Oncol. 2008 Oct;10(5):734-44 [18650489.001]
  • [Cites] Hum Brain Mapp. 2008 Dec;29(12):1368-78 [18064590.001]
  • [Cites] Brain. 2009 Jan;132(Pt 1):213-24 [18952674.001]
  • [Cites] Neurobiol Dis. 2009 Mar;33(3):436-47 [19135151.001]
  • [Cites] Nat Rev Neurosci. 2009 Mar;10(3):186-98 [19190637.001]
  • [Cites] Seizure. 2009 Jul;18(6):392-5 [19269864.001]
  • [Cites] PLoS One. 2009;4(11):e8081 [19956634.001]
  • [Cites] Science. 2009 Dec 4;326(5958):1419-24 [19965761.001]
  • [Cites] J Neurosci. 2009 Dec 16;29(50):15684-93 [20016083.001]
  • [Cites] PLoS One. 2010;5(1):e8525 [20072616.001]
  • [Cites] Clin Neurophysiol. 2010 Feb;121(2):172-85 [20045375.001]
  • [Cites] PLoS One. 2010;5(5):e10839 [20520774.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(1):1-15 [10664370.001]
  • [Cites] Epilepsy Res. 2000 Dec;42(2-3):105-15 [11074183.001]
  • [Cites] Clin Neurophysiol. 2002 Apr;113(4):586-96 [11956004.001]
  • [Cites] Int J Psychophysiol. 2002 Oct;46(1):53-66 [12374646.001]
  • [Cites] Nature. 2003 Feb 20;421(6925):844-8 [12594513.001]
  • [Cites] Neurosci Lett. 2004 Jan 23;355(1-2):25-8 [14729226.001]
  • [Cites] Clin Neurophysiol. 2004 Jun;115(6):1436-41 [15134712.001]
  • [Cites] Seizure. 2004 Sep;13(6):366-74 [15276139.001]
  • [Cites] Clin Neurophysiol. 2004 Oct;115(10):2292-307 [15351371.001]
  • [Cites] Electroencephalogr Clin Neurophysiol. 1980 Aug;49(3-4):345-51 [6158411.001]
  • [Cites] Int Disabil Stud. 1988;10(2):64-7 [3042746.001]
  • [Cites] J Neurophysiol. 1989 May;61(5):900-17 [2723733.001]
  • [Cites] Nature. 1998 Jun 4;393(6684):440-2 [9623998.001]
  • [Cites] Brain Res Brain Res Rev. 1999 Apr;29(2-3):169-95 [10209231.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2005 May 29;360(1457):937-46 [16087438.001]
  • [Cites] Hum Brain Mapp. 2005 Nov;26(3):191-8 [15929086.001]
  • [Cites] Ann Neurol. 2006 Jan;59(1):128-38 [16278872.001]
  • [Cites] Neuroimage. 2006 Mar;30(1):245-53 [16253520.001]
  • (PMID = 20731854.001).
  • [ISSN] 1471-2202
  • [Journal-full-title] BMC neuroscience
  • [ISO-abbreviation] BMC Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticonvulsants
  • [Other-IDs] NLM/ PMC2936439
  •  go-up   go-down


66. Olstorn H, Moe MC, Røste GK, Bueters T, Langmoen IA: Transplantation of stem cells from the adult human brain to the adult rat brain. Neurosurgery; 2007 Jun;60(6):1089-98; discussion 1098-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplantation of stem cells from the adult human brain to the adult rat brain.
  • OBJECTIVE: To investigate the migration, proliferation, and differentiation of stem cells and neural progenitor cells (NPCs) from the adult human brain after transplantation into adult rodent brains.
  • METHODS: Adult human NPCs were obtained from temporal lobe specimens removed because of medical intractable epilepsy.
  • The cells were transplanted into the posterior periventricular region above the hippocampus in the brains of either healthy adult rats (control) or rats with selective injury of the hippocampal CA1 region (global ischemia).
  • Cell survival at 10 weeks was 4.7 +/- 0.3% (control, n = 3) and 3.7 +/- 1.1% (ischemia, n = 3); at 16 weeks, cell survival was 3.4 +/- 0.6% (control, n = 2) and 7.2 +/- 1.5% (ischemia, n = 2), i.e., comparable to what has been observed earlier when transplanting embryonic tissue into the human brain or progenitor cells between inbred rats.
  • We did not observe signs of tumor formation or aberrant cell morphology.
  • CONCLUSION: The present study shows that adult human NPCs survive, show targeted migration, proliferate, and differentiate after grafting into the adult rat brain.
  • [MeSH-major] Brain Ischemia / therapy. Stem Cell Transplantation. Stem Cells / cytology. Stem Cells / physiology. Transplantation, Heterologous
  • [MeSH-minor] Adult. Animals. Cell Differentiation. Cell Movement. Cell Proliferation. Humans. Male. Rats. Rats, Sprague-Dawley

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17538384.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


67. Bodner-Adler B, Bodner K, Zeisler H: Primitive neuroectodermal tumor (PNET) of the brain diagnosed during pregnancy. Anticancer Res; 2006 May-Jun;26(3B):2499-501
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive neuroectodermal tumor (PNET) of the brain diagnosed during pregnancy.
  • BACKGROUND: Brain tumors in pregnancy are extremely rare events.
  • A case of a patient with primitive neuroectodermal tumor (PNET) of the brain diagnosed during the second half of pregnancy is reported.
  • CASE REPORT: The first case of PNET of the brain diagnosed in a 26-year-old woman, gravida 1 para 0, in her 20th week of pregnancy is presented.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / therapy. Neuroectodermal Tumors, Primitive / pathology. Neuroectodermal Tumors, Primitive / therapy. Pregnancy Complications, Neoplastic / pathology. Pregnancy Complications, Neoplastic / therapy
  • [MeSH-minor] Adult. Female. Humans. Pregnancy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16821639.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


68. Armstrong TS, Mendoza T, Gning I, Coco C, Cohen MZ, Eriksen L, Hsu MA, Gilbert MR, Cleeland C: Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). J Neurooncol; 2006 Oct;80(1):27-35
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT).
  • BACKGROUND: Symptom occurrence has been shown to predict treatment course and survival in patients with solid tumors.
  • Primary brain tumor (PBT) patients are unique in the occurrence of neurologic symptoms.
  • Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT).
  • The study evaluated the reliability and validity of the MDASI-BT in primary brain tumor patients.
  • Mean symptom severity of items as well as cluster analysis was used to reduce the number of total items to 22 (13 core, 9 brain tumor items).
  • Regression analysis showed more than half (56%) of the variability in symptom severity was explained by brain module items.
  • The MDASI-BT was sensitive to disease severity based on performance status (P<0.001), tumor recurrence (P<0.01), and mean symptom interference (P<0.001).
  • [MeSH-major] Brain Neoplasms / complications. Brain Neoplasms / physiopathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity. Severity of Illness Index. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Neurooncol. 2006 Oct;80(1):37. Gring, T [corrected to Gning, I]
  • (PMID = 16598415.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] Netherlands
  •  go-up   go-down


69. Vieira Santos A, Vilela P, Mateus L, Saraiva PF, Goulão A: [Central nervous system abnormalities namely secondary brain tumors]. Acta Med Port; 2006 Nov-Dec;19(6):451-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Central nervous system abnormalities namely secondary brain tumors].
  • [Transliterated title] Tumor do sistema nervoso central secundário a radioterapia e quimioterapia.
  • The authors speculate about the possibility that this tumor may have been radiation and/or chemotherapy induced.
  • Improvement in neuroimaging techniques, in particular magnetic resonance imaging, has helped characterize Central Nervous System abnormalities, namely secondary brain tumours.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioblastoma / diagnosis. Neoplasms, Second Primary / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17583602.001).
  • [ISSN] 1646-0758
  • [Journal-full-title] Acta médica portuguesa
  • [ISO-abbreviation] Acta Med Port
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


70. Chaichana K, Parker S, Olivi A, Quiñones-Hinojosa A: A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme. J Neurosurg; 2010 May;112(5):997-1004
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme.
  • OBJECT: Glioblastoma multiforme (GBM) is the most common and aggressive type of primary brain tumor in adults.
  • METHODS: Cases involving adult patients who underwent surgery for an intracranial primary (de novo) GBM between 1997 and 2007 at The Johns Hopkins Hospital, an academic tertiary-care institution, were retrospectively reviewed.
  • The preoperative factors, independent of extent of resection and adjuvant therapies (carmustine wafers, temozolomide, and radiation), found to be negatively associated with survival were: age > 60 years (p < 0.0001), Karnofsky performance status score < or = 80 (p < 0.0001), motor deficit (p = 0.02), language deficit (p = 0.001), and periventricular tumor location (p = 0.04).
  • CONCLUSIONS: The present study found that older age, poor performance status, motor deficit, language deficit, and periventricular tumor location independently predicted poorer survival in patients undergoing GBM resection.
  • [MeSH-major] Brain Neoplasms. Glioblastoma. Program Development
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Preoperative Care. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817542.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


71. Galldiks N, Kracht LW, Berthold F, Miletic H, Klein JC, Herholz K, Jacobs AH, Heiss WD: [11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors. J Neurooncol; 2010 Jan;96(2):231-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors.
  • Only a few Methyl-[11C]-L-methionine (MET) positron emission tomography (PET) studies have focused on children and young adults with brain neoplasm.
  • The MET tumor-uptake relative to a corresponding control region was calculated.
  • A receiver operating characteristic (ROC) was performed to determine the MET-uptake value that best distinguishes tumorous from non-tumorous brain lesions.
  • A differentiation between tumorous (n = 39) and non-tumorous brain lesions (n = 9) was possible at a threshold of 1.48 of relative MET-uptake with a sensitivity of 83% and a specificity of 92%, respectively.
  • A differentiation between high grade malignant lesions (mean MET-uptake = 2.00 +/- 0.46) and low grade tumors (mean MET-uptake = 1.84 +/- 0.31) was not possible.
  • MET-PET might be a useful tool to differentiate tumorous from non-tumorous lesions in children and young adults when a decision for further therapy is difficult or impossible from routine structural imaging procedures alone.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Carbon Radioisotopes. Methionine / analogs & derivatives. Positron-Emission Tomography / methods
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Magnetic Resonance Imaging / methods. Male. ROC Curve. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Radiol. 1987 Nov-Dec;28(6):673-81 [2962599.001]
  • [Cites] J Comput Assist Tomogr. 1983 Dec;7(6):1062-6 [6415134.001]
  • [Cites] Pediatr Neurol. 1990 May-Jun;6(3):163-70 [2193641.001]
  • [Cites] J Comput Assist Tomogr. 1992 Sep-Oct;16(5):804-13 [1522276.001]
  • [Cites] J Comput Assist Tomogr. 1994 Jan-Feb;18(1):110-8 [8282858.001]
  • [Cites] Clin Neurol Neurosurg. 1995 Nov;97(4):349-53 [8599907.001]
  • [Cites] J Nucl Med. 1996 Feb;37(2):387-93 [8667081.001]
  • [Cites] Neurology. 1998 May;50(5):1316-22 [9595980.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7163-70 [15534088.001]
  • [Cites] J Neurosurg. 2006 Feb;104(2):238-53 [16509498.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 May;33(5):516-24 [16450140.001]
  • [Cites] Childs Nerv Syst. 2007 Jul;23(7):739-51 [17356889.001]
  • [Cites] Neurosurg Rev. 1999 Dec;22(4):210-4 [10682929.001]
  • [Cites] J Nucl Med. 2000 Jul;41(7):1250-5 [10914918.001]
  • [Cites] J Nucl Med. 2001 Mar;42(3):432-45 [11337520.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Feb;29(2):176-82 [11926379.001]
  • [Cites] Cancer. 2002 Sep 15;95(6):1376-86 [12216107.001]
  • [Cites] Pediatr Neurosurg. 2003 Mar;38(3):146-55 [12601239.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):868-73 [12692687.001]
  • [Cites] J Neuroimaging. 2003 Jul;13(3):269-71 [12889176.001]
  • [Cites] Mol Imaging. 2002 Oct;1(4):309-35 [12926228.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1389-97 [12920486.001]
  • [Cites] J Neuroimaging. 2004 Oct;14(4):372-6 [15358961.001]
  • [Cites] Int J Appl Radiat Isot. 1979 Jul;30(7):393-9 [478664.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • (PMID = 19575148.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; AE28F7PNPL / Methionine; BN630929UL / methionine methyl ester
  • [Other-IDs] NLM/ PMC2808525
  •  go-up   go-down


72. Saraswathy A, Jayasree RS, Baiju KV, Gupta AK, Pillai VP: Optimum wavelength for the differentiation of brain tumor tissue using autofluorescence spectroscopy. Photomed Laser Surg; 2009 Jun;27(3):425-33
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimum wavelength for the differentiation of brain tumor tissue using autofluorescence spectroscopy.
  • OBJECTIVE: The role of autofluorescence spectroscopy in the detection and staging of benign and malignant brain tumors is being investigated in this study, with an additional aim of determining an optimum excitation wavelength for the spectroscopic identification of brain tumors.
  • MATERIALS AND METHODS: The present study involves in-vitro autofluorescence monitoring of different human brain tumor samples to assess their spectroscopic properties.
  • The autofluorescence measurement at four different excitation wavelengths 320, 370, 410, and 470 nm, were carried out for five different brain tumor types: glioma, astrocytoma, meningioma, pituitary adenoma, and schwannoma.
  • RESULTS: The fluorescence spectra of tumor tissues showed significant differences, both in intensity and in spectral profile, from those of adjacent normal brain tissues at all four excitation wavelengths.
  • Of the four excitation wavelengths being considered, 470 nm appeared to be the optimal wavelength for detecting tissue fluorescence of brain tumor tissues.
  • CONCLUSIONS: In conclusion, the spectroscopic luminescence measurements carried out in this study revealed significant differences between tumor tissue and adjacent normal tissue of human brains for all the tumor types tested, except for pituitary adenoma.
  • From the results of this study we conclude that excitation wavelengths ranging from 410-470 nm are most suitable for the detection of brain tumor tissue.
  • This distinction was not clear at other excitation wavelengths.
  • [MeSH-major] Brain Neoplasms / pathology. Spectrometry, Fluorescence / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Algorithms. Astrocytoma / pathology. Child. Child, Preschool. Discriminant Analysis. Female. Glioma / pathology. Humans. Male. Meningioma / pathology. Middle Aged. Neoplasm Staging. Neurilemmoma / pathology. Pituitary Neoplasms / pathology. Principal Component Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19025404.001).
  • [ISSN] 1557-8550
  • [Journal-full-title] Photomedicine and laser surgery
  • [ISO-abbreviation] Photomed Laser Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. Jones LW, Guill B, Keir ST, Carter B S K, Friedman HS, Bigner DD, Reardon DA: Patterns of exercise across the cancer trajectory in brain tumor patients. Cancer; 2006 May 15;106(10):2224-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of exercise across the cancer trajectory in brain tumor patients.
  • BACKGROUND: Exercise may represent a supportive intervention that may complement existing neurooncologic therapies and address a multitude of therapy-induced debilitating side effects in patients with brain tumors.
  • Given the limited evidence, the authors conducted a survey to examine the exercise patterns of brain tumor patients across the cancer trajectory.
  • METHODS: Using a cross-sectional design, 386 brain tumor patients who received treatment at the Brain Tumor Center at Duke University were sent a questionnaire that assessed self-reported exercise behavior prior to diagnosis, during adjuvant therapy, and after the completion of therapy.
  • However, exploratory analyses indicated that males and younger participants may be at the greatest risk of reducing exercise levels after a brain tumor diagnosis.
  • CONCLUSIONS: A relatively high percentage of brain tumor patients are exercising at recommended levels across the cancer trajectory.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / epidemiology. Exercise / physiology. Health Behavior
  • [MeSH-minor] Adult. Age Distribution. Aged. Analysis of Variance. Cross-Sectional Studies. Disease-Free Survival. Female. Humans. Life Style. Male. Middle Aged. Probability. Prognosis. Reference Values. Risk Assessment. Sex Distribution. Sickness Impact Profile. Surveys and Questionnaires. Survival Analysis


74. Pinarbasi H, Silig Y, Gurelik M: Genetic polymorphisms of GSTs and their association with primary brain tumor incidence. Cancer Genet Cytogenet; 2005 Jan 15;156(2):144-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms of GSTs and their association with primary brain tumor incidence.
  • In this study, the association between polymorphisms in these genes and primary brain tumor incidence was investigated in 228 Turkish individuals (75 patients with primary brain tumor and 153 controls).
  • No association was observed between the GSTT1 or GSTP1 Ile105Val polymorphism and brain tumor incidence.
  • Polymorphisms in GSTM1, GSTT1, and GSTP1 did not show association with histopathologic type of brain tumor (glioma or meningioma).
  • Analysis of the polymorphisms in the studied genes and smoking status of the brain tumor patients revealed no statistically significant association.
  • The presented data clearly suggest a relation between brain tumor incidence with GSTM1 null genotype but not with GSTT1 or GSTP1 gene variants.
  • [MeSH-major] Brain Neoplasms / enzymology. Brain Neoplasms / genetics. Glutathione Transferase / genetics. Isoenzymes / genetics. Polymorphism, Genetic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. DNA Primers. Female. Genetic Variation. Glutathione S-Transferase pi. Humans. Incidence. Male. Middle Aged. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642394.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Isoenzymes; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


75. Seo YS, Chung TW, Kim IY, Bom HS, Min JJ: Enhanced detectability of recurrent brain tumor using glucose-loading F-18 FDG PET. Clin Nucl Med; 2008 Jan;33(1):32-3
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced detectability of recurrent brain tumor using glucose-loading F-18 FDG PET.
  • A 43-year-old man with a history of lung cancer, brain metastasis, and gamma knife radiosurgery underwent FDG PET/CT to differentiate recurrence from radiation necrosis.
  • Basal PET/CT scan showed equivocal uptake in the margin of necrotic tumor.
  • Proton magnetic resonance spectroscopy (1H-MRS) showed increased Cho/Cr ratio (1.7), which was consistent with tumor recurrence.
  • The patient underwent whole brain radiotherapy thereafter.
  • It is implicated that hyperglycemia-induced reduction of glucose uptake in recurrent brain tumors was less than in a normal brain, resulting in higher tumor-to-gray matter ratio.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Contrast Media. Diagnosis, Differential. Gadolinium DTPA. Glucose. Humans. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097254.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; IY9XDZ35W2 / Glucose; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


76. Li F, Zhu G, Lin J, Meng H, Wu N, Du Y, Feng H: Photodynamic therapy increases brain edema and intracranial pressure in a rabbit brain tumor model. Acta Neurochir Suppl; 2006;96:422-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy increases brain edema and intracranial pressure in a rabbit brain tumor model.
  • The objective of this study was to evaluate the effect of a single photodynamic therapy (PDT) on brain edema and intracranial pressure (ICP) in a rabbit model of brain tumor.
  • A total of 57 adult New Zealand rabbits were assigned to 3 groups: the PDT group, the tumor group, and the tumor plus PDT group.
  • Rabbits in the PDT group (n = 9) received PDT but no tumor implantation; rabbits in the tumor group (n = 18) received VX2 carcinoma implantation but no PDT; rabbits in the tumor plus PDT group (n = 30) received tumor implantation with subsequent PDT 16 days later.
  • Brain edema and ICP levels were then evaluated.
  • After tumor implantation, ICP increased rapidly (18.43 +/- 1.10 mmHg, 21 days later).
  • PDT alone did not increase ICP, but compared with that in the tumor group, ICP increased significantly in the tumor plus PDT group (9.55 +/- 1.32 vs. 13.31 +/- 1.13 mmHg, p < 0.01) 24 hours after treatment.
  • Brain water content in the tumor group increased rapidly after tumor implantation.
  • PDT again increased perineoplastic brain edema 24 hours after treatment (81.09 +/- 0.97% vs. 78.32 +/- 0.49%, p < 0.01).
  • It should be noted that PDT alone did not induce brain edema.
  • In conclusion, PDT causes transient brain edema and increases ICP in a rabbit brain tumor model.
  • [MeSH-major] Brain Edema / chemically induced. Brain Neoplasms / drug therapy. Intracranial Hypertension / chemically induced. Intracranial Pressure / drug effects. Photochemotherapy / adverse effects. Porphyrins / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16671498.001).
  • [ISSN] 0065-1419
  • [Journal-full-title] Acta neurochirurgica. Supplement
  • [ISO-abbreviation] Acta Neurochir. Suppl.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins
  •  go-up   go-down


77. Yetnikoff L, Labelle-Dumais C, Flores C: Regulation of netrin-1 receptors by amphetamine in the adult brain. Neuroscience; 2007 Dec 19;150(4):764-73
Hazardous Substances Data Bank. AMPHETAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of netrin-1 receptors by amphetamine in the adult brain.
  • Netrin-1 and its receptors, deleted in colorectal cancer (DCC) and UNC-5 homologues (UNC-5), continue to be expressed in the adult brain, although neither their function nor the kinds of events that activate their expression are known.
  • Two lines of evidence suggest a role for netrin-1 in amphetamine-induced dopamine plasticity in the adult.
  • First, DCC is highly expressed by adult dopamine neurons.
  • Second, adult mice with reduced DCC levels do not develop amphetamine-induced behavioral sensitization.
  • To explore the role of netrin-1 in amphetamine-induced plasticity, we examined the effects of sensitizing treatment regimens of amphetamine on DCC and/or UNC-5 protein expression in the adult rat.
  • Using immunohistochemistry, we showed that both DCC and UNC-5 receptors are highly expressed by adult mesocorticolimbic dopamine neurons.
  • These results provide the first evidence that repeated exposure to a stimulant drug such as amphetamine affects netrin-1 receptor expression in the adult brain.
  • Taken together, our findings suggest that changes in netrin-1 receptor expression may play a role in the lasting effects of exposure to amphetamine and other stimulant drugs.
  • [MeSH-major] Amphetamine / pharmacology. Brain / drug effects. Brain / metabolism. Central Nervous System Stimulants / pharmacology. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Animals. Behavior, Animal / drug effects. Drug Interactions. Excitatory Amino Acid Antagonists / pharmacology. Male. Motor Activity / drug effects. Nerve Growth Factors / metabolism. Piperazines / pharmacology. Rats. Rats, Sprague-Dawley. Tumor Suppressor Proteins / metabolism. Tyrosine 3-Monooxygenase / metabolism

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17996376.001).
  • [ISSN] 0306-4522
  • [Journal-full-title] Neuroscience
  • [ISO-abbreviation] Neuroscience
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / / 74709
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 0 / Dcc protein, rat; 0 / Excitatory Amino Acid Antagonists; 0 / Nerve Growth Factors; 0 / Piperazines; 0 / Receptors, Cell Surface; 0 / Tumor Suppressor Proteins; 0 / UNC-5 protein, rat; 0 / netrin receptors; 158651-98-0 / netrin-1; 98Y1I8ZD4M / 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; CK833KGX7E / Amphetamine; EC 1.14.16.2 / Tyrosine 3-Monooxygenase
  • [Other-IDs] NLM/ CAMS1049; NLM/ PMC4880477
  •  go-up   go-down


78. Juan Escudero JU, Ramos de Campos M, Navalón Verdejo P, Cánovas López S, Fabuel Deltoro M, Serrano de la Cruz Torrijos F, Ramada Benlloch F, Marques Vidal E, Martínez León J: [Surgical treatment of renal tumours with venous extension]. Arch Esp Urol; 2009 Jan-Feb;62(1):9-16
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Tratamiento quirúrgico del tumor renal con extensión venosa.
  • OBJECTIVES: Renal carcinoma accounts for 3% of malignant urological tumors.
  • The existence of tumor thrombus in the venous system is more infrequent, and, despite it was believed until recently its presence worsened the diagnosis of the disease, currently it is accepted that in the absence of metastatic or lymph node disease, surgery is the treatment of choice and potentially curative for these tumors.
  • RESULTS: Tumor thrombus was grade I in one patient, grade II in 4 patients, grade III in one patient, and grade IV in two patients.
  • In all patients with tumor grade > or = III, as well as two with grade II, surgery was performed in conjunction with the department of heart surgery.
  • The operation with extracorporeal circulation, deep hypothermia, cardioplegia, and antegrade and retrograde brain perfusion was performed in grades III and IV.
  • DISCUSSION: It is essential to know the exact level of the cephalic extreme of the tumor thrombus to design the proper surgical strategy; for that, we can use MRI, CT scan or ultrasound.
  • After radical surgery survival rates achieved are similar to those of tumors without venous thrombus.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Kidney Neoplasms / surgery. Neoplastic Cells, Circulating. Renal Veins. Vena Cava, Inferior
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19400441.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


79. Jensen TR, Schmainda KM: Computer-aided detection of brain tumor invasion using multiparametric MRI. J Magn Reson Imaging; 2009 Sep;30(3):481-9
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-aided detection of brain tumor invasion using multiparametric MRI.
  • PURPOSE: To determine the potential of using a computer-aided detection method to intelligently distinguish peritumoral edema alone from peritumor edema consisting of tumor using a combination of high-resolution morphological and physiological magnetic resonance imaging (MRI) techniques available on most clinical MRI scanners.
  • MATERIALS AND METHODS: This retrospective study consisted of patients with two types of primary brain tumors: meningiomas (n = 7) and glioblastomas (n = 11).
  • Meningiomas are typically benign and have a clear delineation of tumor and edema.
  • Four classifiers of differing designs were trained using morphological, diffusion-weighted, and perfusion-weighted features derived from MRI to discriminate tumor and edema, tested on edematous regions surrounding tumors, and assessed for their ability to detect nonenhancing tumor invasion.
  • Each classifier was able to identify areas of nonenhancing tumor invasion supported with adjunct images or follow-up studies.
  • CONCLUSION: The combination of features derived from morphological and physiological imaging techniques contains the information necessary for computer-aided detection of tumor invasion and allows for the identification of tumor invasion not previously visualized on morphological, diffusion-weighted, and perfusion-weighted images and maps.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19711398.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA028500; United States / NCRR NIH HHS / RR / M01 RR000058; United States / NCI NIH HHS / CA / R21 CA109280; United States / NCI NIH HHS / CA / R01 CA082500; United States / NCRR NIH HHS / RR / M01-RR00058; United States / NCI NIH HHS / CA / R21 CA10928; United States / NCI NIH HHS / CA / R01 CA082500-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 84F6U3J2R6 / gadodiamide; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ NIHMS185656; NLM/ PMC4321878
  •  go-up   go-down


80. Marzinke MA, Henderson EM, Yang KS, See AW, Knutson DC, Clagett-Dame M: Calmin expression in embryos and the adult brain, and its regulation by all-trans retinoic acid. Dev Dyn; 2010 Feb;239(2):610-9
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calmin expression in embryos and the adult brain, and its regulation by all-trans retinoic acid.
  • In embryonic day 18.5 embryos, CLMN is detected in regions where newly differentiated neurons are found, including the neural retina and the cortical plate; and in the adult brain, CLMN is most highly expressed in the neuron cell bodies of the hippocampus, cerebellum, and olfactory bulb.
  • Thus, Clmn is sensitive to retinoid status during early gestational stages, and its expression is relegated to postmitotic neuronal cells in the adult rat brain.
  • [MeSH-major] Brain / metabolism. Membrane Proteins / metabolism. Neural Tube / metabolism. Neurons / metabolism. Tretinoin / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Down-Regulation. Gene Library. Immunoblotting. Immunohistochemistry. In Situ Hybridization. Mice. Microfilament Proteins. RNA, Messenger / metabolism. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20014094.001).
  • [ISSN] 1097-0177
  • [Journal-full-title] Developmental dynamics : an official publication of the American Association of Anatomists
  • [ISO-abbreviation] Dev. Dyn.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLMN protein, rat; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / RNA, Messenger; 5688UTC01R / Tretinoin
  •  go-up   go-down


81. Takei H, Adesina AM, Mehta V, Powell SZ, Langford LA: Atypical teratoid/rhabdoid tumor of the pineal region in an adult. J Neurosurg; 2010 Aug;113(2):374-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumor of the pineal region in an adult.
  • An atypical teratoid/rhabdoid tumor (AT/RT) is a highly malignant embryonal tumor most often occurring in the posterior fossa in children younger than 3 years of age.
  • Adult cases of AT/RT are very rare, and 27 cases with a diagnosis of either AT/RT or (malignant) rhabdoid tumor have been reported to date.
  • The authors report an adult case of an AT/RT occurring in the pineal region with molecular cytogenetic and immunohistochemical confirmation.
  • She underwent a subtotal resection of the tumor and was then treated with chemoradiation.
  • Histological sections showed epithelioid cellular sheets of rhabdoid tumor cells with scattered mitotic figures.
  • Immunohistochemically, the tumor cells were diffusely and strongly positive for epithelial membrane antigen and vimentin, and showed focal expression of glial fibrillary acidic protein, pancytokeratin, and neurofilament protein.
  • Histologically, this tumor consisted exclusively of epithelioid tumor cells with rhabdoid features.
  • Molecular testing to identify monosomy 22 or deletions of the chromosome 22q11 containing the INI1/hSNF5 gene and/or immunohistochemical staining with INI1 antibody is of great importance for the diagnosis of this tumor.
  • [MeSH-major] Brain Neoplasms / pathology. Pinealoma / pathology. Rhabdoid Tumor / pathology. Teratoma / pathology
  • [MeSH-minor] Adult. Biopsy. Chromosomal Proteins, Non-Histone / genetics. Chromosomes, Human, Pair 22. DNA-Binding Proteins / genetics. Female. Gene Deletion. Humans. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Transcription Factors / genetics

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19911885.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


82. Loiseau H, Huchet A, Rué M, Cowppli-Bony A, Baldi I: [Epidemiology of primary brain tumor]. Rev Neurol (Paris); 2009 Aug-Sep;165(8-9):650-70
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiology of primary brain tumor].
  • Two main approaches are generally used to study the epidemiology of primary brain tumors.
  • Descriptive epidemiological studies have reported an increasing annual incidence of primary brain tumors in industrialized countries.
  • In all registries, weak incidence of primary brain tumors constitute a very important limiting factor.
  • [MeSH-major] Brain Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Autoimmune Diseases / epidemiology. Child. Child, Preschool. Environmental Exposure. Ethnic Groups. Female. Genetic Predisposition to Disease. Humans. Infant. Infant, Newborn. Male. Middle Aged. Polymorphism, Genetic. Risk Factors. Sex Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19446856.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 210
  •  go-up   go-down


83. Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA: Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res; 2008 Apr 15;14(8):2378-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary biomarkers predict brain tumor presence and response to therapy.
  • PURPOSE: A major difficulty in treating brain tumors is the lack of effective methods of identifying novel or recurrent disease.
  • In this study, we have evaluated the efficacy of urinary matrix metalloproteinases (MMP) as diagnostic biomarkers for brain tumors.
  • EXPERIMENTAL DESIGN: Urine, cerebrospinal fluid, and tissue specimens were collected from patients with brain tumors.
  • RESULTS: Evaluation of a specific panel of urinary biomarkers by ELISA showed significant elevations of MMP-2, MMP-9, MMP-9/NGAL, and VEGF (all P < 0.001) in samples from brain tumor patients compared with controls.
  • Multiplexing MMP-2 and VEGF provided superior accuracy compared with any other combination or individual biomarker.
  • Immunohistochemistry identified these same proteins in the source tumor tissue.
  • A subset of patients with longitudinal follow-up revealed subsequent clearing of biomarkers after tumor resection.
  • CONCLUSION: We report, for the first time, the identification of a panel of urinary biomarkers that predicts the presence of brain tumors.
  • These data support the hypothesis that urinary MMPs and associated proteins are useful predictors of the presence of brain tumors and may provide a basis for a novel, noninvasive method to identify new brain tumors and monitor known tumors after treatment.
  • [MeSH-major] Acute-Phase Proteins / urine. Biomarkers, Tumor / urine. Brain Neoplasms / diagnosis. Lipocalins / urine. Matrix Metalloproteinase 2 / urine. Matrix Metalloproteinase 9 / urine. Proto-Oncogene Proteins / urine. Vascular Endothelial Growth Factor A / urine
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Infant. Infant, Newborn. Longitudinal Studies. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18413828.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK065298; United States / NCI NIH HHS / CA / K12CA90354; United States / NCI NIH HHS / CA / P01CA45548
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / Biomarkers, Tumor; 0 / LCN2 protein, human; 0 / Lipocalins; 0 / Proto-Oncogene Proteins; 0 / Vascular Endothelial Growth Factor A; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


84. Newton HB, Goldlust SA, Pearl D: Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol; 2006 May;78(1):99-102
Hazardous Substances Data Bank. PIRACETAM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients.
  • Seizures are a common complication of primary (PBT) and metastatic (MBT) brain tumors, affecting approximately 50% of all patients during the course of their illness.
  • Anti-convulsant therapy of these tumor-induced seizures is often inadequate with conventional anti-epileptic drugs (AEDs), due to a variety of factors, including activation of glutaminergic NMDA receptors, immune-mediated neuronal damage, and anatomic alterations of neuronal input pathways.
  • Because of this unique mechanism, it has been postulated that LEV may be effective in controlling tumor-induced seizures.
  • LEV was very effective and well tolerated in brain tumor patients with seizures, and should be considered for add-on therapy to current AEDs, or as a substitute anti-convulsant for monotherapy.
  • [MeSH-major] Anticonvulsants / therapeutic use. Brain Neoplasms / complications. Piracetam / analogs & derivatives. Seizures / drug therapy. Seizures / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Seizures.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16541329.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16058
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anticonvulsants; 230447L0GL / etiracetam; ZH516LNZ10 / Piracetam
  •  go-up   go-down


85. Chan MD, Tatter SB, Lesser G, Shaw EG: Radiation oncology in brain tumors: current approaches and clinical trials in progress. Neuroimaging Clin N Am; 2010 Aug;20(3):401-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation oncology in brain tumors: current approaches and clinical trials in progress.
  • Radiation therapy remains a critical therapeutic modality in the treatment of adult brain tumors.
  • However, its use continues to evolve depending on the histologic findings of the brain tumor.
  • In low-grade gliomas, the life expectancy is much greater, and the possibility of late effects of radiotherapy have shaped contemporary trials to attempt to identify groups that benefit from radiotherapy versus the ones that may defer radiotherapy until tumor progression.
  • With meningioma, the use of normal tissue-sparing techniques such as radiosurgery has allowed for the successful treatment of patients who are eminently curable and with a life expectancy that is generally no different than that of the general population.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Glioma / radiotherapy. Lymphoma / radiotherapy. Meningioma / radiotherapy. Radiation Oncology / methods. Randomized Controlled Trials as Topic / methods
  • [MeSH-minor] Adult. Glioblastoma / radiotherapy. Glioblastoma / therapy. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20708554.001).
  • [ISSN] 1557-9867
  • [Journal-full-title] Neuroimaging clinics of North America
  • [ISO-abbreviation] Neuroimaging Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


86. Ohue S, Kumon Y, Nagato S, Kohno S, Harada H, Nakagawa K, Kikuchi K, Miki H, Ohnishi T: Evaluation of intraoperative brain shift using an ultrasound-linked navigation system for brain tumor surgery. Neurol Med Chir (Tokyo); 2010;50(4):291-300
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of intraoperative brain shift using an ultrasound-linked navigation system for brain tumor surgery.
  • Image-guided neurosurgery using navigation systems is an essential tool to increase accuracy in brain tumor surgery.
  • However, brain shift during surgery has remained problematic.
  • The present study evaluated the utility of a new ultrasound (US)-linked navigation system for brain tumor surgery in 64 patients with intracranial tumors.
  • The system was used intraoperatively to measure brain shift several times, using the results to guide tumor resection.
  • US-linked navigation provided information regarding brain shift, and extent of tumor resection during surgery.
  • Evaluation of brain shift was easily achieved in all patients, without using intraoperative CT or MR imaging.
  • Magnitude of brain shift increased progressively from pre- to post-resection and depended on the type of cranial structure.
  • The system also improved the rate of tumor resection by facilitating the detection of remnant tumor tissue.
  • This US-linked navigation system provides information on brain shift, and improves the accuracy and utility of image-guided surgery.
  • [MeSH-major] Brain Mapping / methods. Brain Neoplasms / ultrasonography. Neuronavigation / methods. Surgery, Computer-Assisted / methods. Ultrasonography
  • [MeSH-minor] Adolescent. Adult. Aged. Anatomy, Regional / instrumentation. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Monitoring, Intraoperative / instrumentation. Monitoring, Intraoperative / methods. Movement. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20448420.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


87. Kinoshita M, Hashimoto N, Goto T, Kagawa N, Kishima H, Izumoto S, Tanaka H, Fujita N, Yoshimine T: Fractional anisotropy and tumor cell density of the tumor core show positive correlation in diffusion tensor magnetic resonance imaging of malignant brain tumors. Neuroimage; 2008 Oct 15;43(1):29-35
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractional anisotropy and tumor cell density of the tumor core show positive correlation in diffusion tensor magnetic resonance imaging of malignant brain tumors.
  • A noninvasive technique for assessing tumor tissue characteristics is required to assist preoperative surgical planning for malignant brain tumors.
  • Preoperative information on tumor cell density within a tumor would help better define the target for tumor biopsy, resulting in more accurate diagnosis and grading of malignant brain tumors.
  • One possible source of this information is diffusion tensor imaging (DTI), although to date studies have focused on its ability to delineate white matter fiber tracks by fiber-tracking and to detect tumor infiltration around the tumor and normal white matter interface.
  • In the present study we performed a retrospective investigation of tumor cell density and FA and MD values in biopsy cases.
  • We found that FA has a good positive correlation (R=0.75) and MD has a good negative correlation (R=0.70) with tumor cell density within the tumor core.
  • Thus, measurement of both FA and MD within the tumor core has a potential to provide detailed information on tumor cell density within the tumor.
  • Although data obtained from DTI should be interpreted carefully and comprehensively with other imaging modalities such as positron emission tomography, DTI seems to be informative for planning the best biopsy target containing the highest cell density.
  • [MeSH-major] Algorithms. Brain Neoplasms / pathology. Cell Count / methods. Diffusion Magnetic Resonance Imaging / methods. Image Interpretation, Computer-Assisted / methods
  • [MeSH-minor] Adult. Aged. Anisotropy. Child. Child, Preschool. Female. Humans. Image Enhancement / methods. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity. Statistics as Topic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672074.001).
  • [ISSN] 1095-9572
  • [Journal-full-title] NeuroImage
  • [ISO-abbreviation] Neuroimage
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


88. Sgubin D, Aztiria E, Perin A, Longatti P, Leanza G: Activation of endogenous neural stem cells in the adult human brain following subarachnoid hemorrhage. J Neurosci Res; 2007 Jun;85(8):1647-55
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of endogenous neural stem cells in the adult human brain following subarachnoid hemorrhage.
  • In the adult human brain, the presence of neural stem cells has been documented in the subgranular layer of the dentate gyrus of the hippocampus and in the subventricular zone of the lateral ventricles.
  • Neurogenesis has also been reported in rodent models of ischemic stroke, traumatic brain injury, epileptic seizures, and intracerebral or subarachnoid hemorrhage.
  • However, only sparse information is available about the occurrence of neurogenesis in the human brain under similar pathological conditions.
  • In the present report, we describe neural progenitor cell proliferation in the brain of patients suffering from subarachnoid hemorrhage (SAH) resulting from ruptured aneurysm.
  • Ten cerebral samples from both SAH and control patients obtained, respectively, during aneurysm clipping and deep brain tumor removal were analyzed by reverse transcription followed by polymerase chain reaction (RT-PCR) and/or immunohistochemistry (IHC).
  • Thus, activation of neural progenitor cell proliferation may occur in adult human brain following subarachnoid hemorrhage, possibly contributing to the promotion of spontaneous recovery, in this pathological condition.
  • [MeSH-minor] Adult. Aged. Aneurysm, Ruptured / complications. Biomarkers / metabolism. Cell Proliferation. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Intracranial Aneurysm / complications. Male. Microscopy, Confocal. Microscopy, Fluorescence. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17455304.001).
  • [ISSN] 0360-4012
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


89. Yoshimura J, Nishiyama K, Fukuda M, Watanabe M, Igarashi H, Fujii Y: Adult cerebellopontine angle medulloblastoma originating in the pons mimicking focal brainstem tumor. J Neuroimaging; 2009 Oct;19(4):385-7
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult cerebellopontine angle medulloblastoma originating in the pons mimicking focal brainstem tumor.
  • MR spectroscopic imaging is considered to be quite useful for the management of this rare type of brainstem tumor.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Cerebellopontine Angle / pathology. Infratentorial Neoplasms / pathology. Medulloblastoma / pathology. Pons / pathology
  • [MeSH-minor] Adult. Aspartic Acid / analogs & derivatives. Aspartic Acid / metabolism. Choline / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Functional Laterality. Humans. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19021841.001).
  • [ISSN] 1552-6569
  • [Journal-full-title] Journal of neuroimaging : official journal of the American Society of Neuroimaging
  • [ISO-abbreviation] J Neuroimaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate; N91BDP6H0X / Choline
  •  go-up   go-down


90. Fang JS, Deng YW, Li MC, Chen FH, Wang YJ, Lu M, Fang F, Wu J, Yang ZY, Zhou XY, Wang F, Chen C: [Isolation and identification of brain tumor stem cells from human brain neuroepithelial tumors]. Zhonghua Yi Xue Za Zhi; 2007 Jan 30;87(5):298-303
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Isolation and identification of brain tumor stem cells from human brain neuroepithelial tumors].
  • OBJECTIVE: To establish a simplified culture system for the isolation of brain tumor stem cells (BTSCs) from the tumors of human neuroepithelial tissue, to observe the growth and differentiation pattern of BTSCs, and to investigate their expression of the specific markers.
  • METHODS: Twenty-six patients with brain neuroepithelial tumors underwent tumor resection.
  • Two pieces of tumor tissues were taken from each tumor to be dissociated, triturated into single cells in sterile DMEM-F12 medium, and then filtered.
  • The tumor cells were seeded at a concentration of 200,000 viable cells per mL into serum-free DMEM-F12 medium simply supplemented with B27, human basic fibroblast growth factor (20 microg/L), human epidermal growth factor (20 microg /L), insulin (4 U/L), L-glutamine, penicillin and streptomycin.
  • After the primary brain tumor spheres (BTSs) were generated, they were triturated again and passed in fresh medium.
  • RESULTS: Only a minority of subsets of cells from the tumors of neuroepithelial tissue had the capacity to survive, proliferate, and generate free-floating neurosphere-like BTSs in the simplified serum-free medium.
  • The rate of CD133 positive cells in the tumor specimens was (21 +/- 6.2)% - (38 +/- 7.0)%.
  • The tumors of human neuroepithelial tissue contain CD133 and nestin positive tumor stem cells which can be isolated, proliferate and differentiate in vitro and give rise to brain tumor spheres.
  • This tumorigenic subset may provide both a platform for brain tumor research and a target for clinical treatment.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasms, Neuroepithelial / pathology. Neoplastic Stem Cells / pathology
  • [MeSH-minor] Adolescent. Adult. Cell Proliferation / drug effects. Child. Culture Media, Serum-Free / pharmacology. Female. Humans. Male. Middle Aged. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17456355.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Culture Media, Serum-Free
  •  go-up   go-down


91. Roberge D, Petrecca K, El Refae M, Souhami L: Whole-brain radiotherapy and tumor bed radiosurgery following resection of solitary brain metastases. J Neurooncol; 2009 Oct;95(1):95-99
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole-brain radiotherapy and tumor bed radiosurgery following resection of solitary brain metastases.
  • A standard approach to solitary brain metastases is resection followed by whole-brain radiation therapy (WBRT).
  • Despite WBRT, the tumor bed remains a common site of failure.
  • We reviewed outcomes following adjuvant WBRT with tumor bed radiosurgery (SRS).
  • We retrospectively identified patients having undergone neurosurgical resection of a single brain metastasis followed by adjuvant WBRT and tumor bed SRS.
  • From 2005 to 2008, 27 patients were treated with WBRT and tumor bed SRS.
  • Radiosurgery can be safely added to WBRT as an adjuvant treatment following resection of a single brain metastasis.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Neurosurgery / methods. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Magnetic Resonance Imaging / methods. Male. Middle Aged. Radiotherapy Dosage. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19381439.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Da Silva AN, Schiff D: Adrenal insufficiency secondary to glucocorticoid withdrawal in patients with brain tumor. Surg Neurol; 2007 May;67(5):508-10
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal insufficiency secondary to glucocorticoid withdrawal in patients with brain tumor.
  • BACKGROUND: Glucocorticoids are the main drug used to control vasogenic edema in patients with brain tumor.
  • [MeSH-major] Adrenal Insufficiency / chemically induced. Brain Edema / drug therapy. Brain Edema / etiology. Brain Neoplasms / complications. Glucocorticoids / adverse effects. Substance Withdrawal Syndrome / physiopathology
  • [MeSH-minor] Adrenocorticotropic Hormone / blood. Adult. Aged. Causality. Cosyntropin. Drug Administration Schedule. Female. Humans. Hypothalamo-Hypophyseal System / physiopathology. Intracranial Hypertension / drug therapy. Intracranial Hypertension / etiology. Intracranial Hypertension / prevention & control. Male. Middle Aged. Patient Selection

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. Cosyntropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17445619.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 16960-16-0 / Cosyntropin; 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


93. Wright AJ, Fellows GA, Griffiths JR, Wilson M, Bell BA, Howe FA: Ex-vivo HRMAS of adult brain tumours: metabolite quantification and assignment of tumour biomarkers. Mol Cancer; 2010;9:66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ex-vivo HRMAS of adult brain tumours: metabolite quantification and assignment of tumour biomarkers.
  • RESULTS: 1D and 2D 1H HRMAS NMR was used to determine that 29 small molecule metabolites, along with 8 macromolecule signals, account for the majority of the HRMAS spectrum of the main types of brain tumour (astrocytoma grade II, grade III gliomas, glioblastomas, metastases, meningiomas and also lymphomas).
  • Differences in concentration of 20 of these metabolites were statistically significant between these brain tumour types.
  • CONCLUSIONS: A number of small molecule metabolites have been identified as potential biomarkers of tumour type that may enable development of more selective in-vivo 1H NMR acquisition methods for diagnosis and prognosis of brain tumours.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Magnetic Resonance Spectroscopy / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4B):3125-32 [10652601.001]
  • [Cites] NMR Biomed. 2000 May;13(3):129-53 [10861994.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Oct;21(9):1645-9 [11039343.001]
  • [Cites] Neuro Oncol. 2000 Apr;2(2):87-95 [11303625.001]
  • [Cites] Int J Mol Med. 2002 Mar;9(3):299-310 [11836637.001]
  • [Cites] Eur Radiol. 2002 Feb;12(2):329-40 [11870430.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1890-7 [11912170.001]
  • [Cites] J Neurosurg. 2002 Jun;96(6):1023-31 [12066902.001]
  • [Cites] NMR Biomed. 2002 Aug;15(5):327-37 [12203224.001]
  • [Cites] NMR Biomed. 2002 Oct;15(6):375-84 [12357551.001]
  • [Cites] Magn Reson Med. 2003 Apr;49(4):632-7 [12652533.001]
  • [Cites] NMR Biomed. 2003 May;16(3):123-31 [12884355.001]
  • [Cites] Magn Reson Imaging. 2003 Jul;21(6):663-72 [12915198.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):45915-23 [12954643.001]
  • [Cites] Magn Reson Med. 2004 Feb;51(2):225-9 [14755644.001]
  • [Cites] NMR Biomed. 2004 Jun;17(4):191-205 [15229932.001]
  • [Cites] J Magn Reson Imaging. 2004 Aug;20(2):187-92 [15269942.001]
  • [Cites] Magn Reson Med. 1992 Mar;24(1):123-36 [1556919.001]
  • [Cites] Neurol Med Chir (Tokyo). 1993 Jun;33(6):350-9 [7689180.001]
  • [Cites] Magn Reson Med. 1993 Dec;30(6):672-9 [8139448.001]
  • [Cites] J Neurochem. 1994 Oct;63(4):1538-43 [7931308.001]
  • [Cites] NMR Biomed. 1995 Sep;8(6):253-64 [8732181.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6408-13 [9177231.001]
  • [Cites] NMR Biomed. 1997 Jan;10(1):2-12 [9251109.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1997 Jul;43(5):659-73 [9298589.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1825-32 [9581820.001]
  • [Cites] J Neurochem. 1998 Aug;71(2):827-32 [9681475.001]
  • [Cites] J Magn Reson. 1999 Nov;141(1):104-20 [10527748.001]
  • [Cites] Magn Reson Med. 2005 Jan;53(1):41-8 [15690501.001]
  • [Cites] NMR Biomed. 2005 Oct;18(6):371-82 [15959923.001]
  • [Cites] Eur J Radiol. 2006 Jun;58(3):394-403 [16527438.001]
  • [Cites] NMR Biomed. 2006 Jun;19(4):411-34 [16763971.001]
  • [Cites] Int J Mol Med. 2006 Nov;18(5):859-69 [17016616.001]
  • [Cites] Magn Reson Med. 2006 Dec;56(6):1211-9 [17029227.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D521-6 [17202168.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D402-8 [17984079.001]
  • [Cites] Magn Reson Med. 2008 Jun;59(6):1266-73 [18506844.001]
  • [Cites] Exp Neurol. 2008 Aug;212(2):377-85 [18538323.001]
  • [Cites] NMR Biomed. 2008 Aug;21(7):677-85 [18186027.001]
  • [Cites] Magn Reson Med. 2008 Nov;60(5):1237-42 [18836999.001]
  • [Cites] Eur Radiol. 2008 Dec;18(12):2901-11 [18641997.001]
  • [Cites] NMR Biomed. 2008 Nov;21(10):1138-47 [18666093.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D603-10 [18953024.001]
  • [Cites] NMR Biomed. 2009 Feb;22(2):213-9 [19067434.001]
  • [Cites] Acta Radiol. 2009 Mar;50(2):217-25 [19096950.001]
  • [Cites] Mol Cancer. 2009;8:6 [19208232.001]
  • [Cites] Neurotherapeutics. 2009 Jul;6(3):598-603 [19560748.001]
  • [Cites] NMR Biomed. 2009 Jul;22(6):629-37 [19322812.001]
  • [Cites] J Magn Reson Imaging. 2010 Feb;31(2):289-97 [20099340.001]
  • (PMID = 20331867.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0601327
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2858738
  •  go-up   go-down


94. Fattori S, Becherini F, Cianfriglia M, Parenti G, Romanini A, Castagna M: Human brain tumors: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells. Virchows Arch; 2007 Jul;451(1):81-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human brain tumors: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells.
  • Malignant brain tumor is a lethal disease with currently available treatment options having a limited impact on outcome.
  • The fine characterization of the MDR1 gene encoding for P-glycoprotein (MDR1-Pgp) in brain tumors may be a crucial determinant for evaluating the long-term efficiency of specific anti-cancer compounds.
  • By using a very high specific monoclonal antibody, the MDR1-Pgp was immunodetected in 34 out of 43 grade IV, 6 out of 10 grade III, 4 out of 7 grade II, and 1 out 3 grade I brain tumors.
  • MDR1-Pgp resulted hyper-expressed, both in vessels and in neoplastic cells from the majority of tumors examined, compared to normal parenchyma.
  • This study demonstrates that the MDR1 gene can be detected in all grade tumor brain malignancies and in endothelial cells of newly formed capillaries, thus, impairing drug access at the tumor cell level.
  • Although the role of MDR1-Pgp in tumor blood vessels needs to be further examined and more clearly defined, drug resistance in malignant brain tumors may result from characteristics not only of tumor vasculature but also of neoplastic cells.
  • [MeSH-major] Brain Neoplasms / drug therapy. Endothelial Cells / chemistry. P-Glycoprotein / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Capillaries / chemistry. Drug Resistance, Neoplasm. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593388.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / P-Glycoprotein
  •  go-up   go-down


95. Keir ST: Levels of stress and intervention preferences of caregivers of brain tumor patients. Cancer Nurs; 2007 Nov-Dec;30(6):E33-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levels of stress and intervention preferences of caregivers of brain tumor patients.
  • The purpose of this pilot study was to assess the level of stress experienced by caregivers of brain tumor patients and to examine both their interest in and preferences for stress reduction programs.
  • Using a convenience sample of 60 adult caregivers, we distributed a study questionnaire that examined the caregivers' level of stress, beliefs, past experiences, and preferences in regard to stress reduction programs.
  • Ninety percent of the caregivers preferred programs that could be undertaken in their own homes either alone (37%), with a spouse (35%), or with the brain tumor patient for whom they were providing care (28%).
  • [MeSH-major] Brain Neoplasms / nursing. Caregivers / psychology. Consumer Behavior. Relaxation Therapy. Stress, Psychological / prevention & control
  • [MeSH-minor] Adult. Aged. Female. Health Knowledge, Attitudes, Practice. Humans. Male. Middle Aged. Pilot Projects. Southeastern United States

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Caregivers.
  • MedlinePlus Health Information. consumer health - Stress.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18025910.001).
  • [ISSN] 1538-9804
  • [Journal-full-title] Cancer nursing
  • [ISO-abbreviation] Cancer Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


96. Deltour I, Johansen C, Auvinen A, Feychting M, Klaeboe L, Schüz J: Time trends in brain tumor incidence rates in Denmark, Finland, Norway, and Sweden, 1974-2003. J Natl Cancer Inst; 2009 Dec 16;101(24):1721-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time trends in brain tumor incidence rates in Denmark, Finland, Norway, and Sweden, 1974-2003.
  • In Denmark, Finland, Norway, and Sweden, the use of mobile phones increased sharply in the mid-1990s; thus, time trends in brain tumor incidence after 1998 may provide information about possible tumor risks associated with mobile phone use.
  • During this period, 59,984 men and women aged 20-79 years were diagnosed with brain tumors in a population of 16 million adults.
  • [MeSH-major] Brain Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Denmark / epidemiology. Female. Finland / epidemiology. Glioma / epidemiology. Humans. Incidence. Male. Meningeal Neoplasms / epidemiology. Meningioma / epidemiology. Middle Aged. Norway / epidemiology. Registries. Sweden / epidemiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2010 May 19;102(10):740-1; author reply 742-3 [20403845.001]
  • [CommentIn] J Natl Cancer Inst. 2010 May 19;102(10):741-2; author reply 742-3 [20403846.001]
  • (PMID = 19959779.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


97. Pace A, Parisi C, Di Lelio M, Zizzari A, Petreri G, Giovannelli M, Pompili A: Home rehabilitation for brain tumor patients. J Exp Clin Cancer Res; 2007 Sep;26(3):297-300
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Home rehabilitation for brain tumor patients.
  • To determine whether a program of post-discharge rehabilitation at home for patients operated for brain tumor was associated with functional gain and improvement in Quality of Life (QoL).
  • One hundred and twenty-one patients affected by malignant brain tumor were enrolled in a program of post-discharge home care including neurorehabilitation.
  • Rehabilitation at home in brain tumor patients was associated with significant functional gain measured both with BI and KPS.
  • [MeSH-major] Brain Neoplasms / rehabilitation
  • [MeSH-minor] Adolescent. Adult. Aged. Home Care Services. Humans. Middle Aged. Palliative Care. Quality of Life. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17987786.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


98. Tchaicha JH, Mobley AK, Hossain MG, Aldape KD, McCarty JH: A mosaic mouse model of astrocytoma identifies alphavbeta8 integrin as a negative regulator of tumor angiogenesis. Oncogene; 2010 Aug 5;29(31):4460-72
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mosaic mouse model of astrocytoma identifies alphavbeta8 integrin as a negative regulator of tumor angiogenesis.
  • Furthermore, little is known about how cancer cells selectively circumvent the actions of these inhibitors to promote pathological angiogenesis, a requisite event for tumor progression.
  • Using mosaic mouse models of the malignant brain cancer, astrocytoma, we report that tumor cells induce pathological angiogenesis by suppressing expression of the ECM protein receptor alphavbeta8 integrin.
  • Diminished integrin expression in astrocytoma cells leads to reduced activation of latent TGFbetas, resulting in impaired TGFbeta receptor signaling in tumor-associated endothelial cells.
  • Finally, these results show that an adhesion and signaling axis normally involved in developmental brain angiogenesis is pathologically exploited in adult brain tumors.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Methods Enzymol. 2006;419:3-23 [17141049.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] J Cell Sci. 2007 May 15;120(Pt 10):1810-7 [17502485.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jun;8(6):464-78 [17522591.001]
  • [Cites] Glia. 2007 Aug 1;55(10):1023-33 [17549683.001]
  • [Cites] Nat Rev Neurosci. 2007 Aug;8(8):610-22 [17643088.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2683-710 [17974913.001]
  • [Cites] Mech Dev. 2008 May-Jun;125(5-6):508-16 [18343643.001]
  • [Cites] Am J Pathol. 2008 Jun;172(6):1740-7 [18467691.001]
  • [Cites] Cell. 2008 Jul 25;134(2):215-30 [18662538.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1129-33 [18948956.001]
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):45-56 [19111880.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3308-16 [19351861.001]
  • [Cites] Curr Opin Hematol. 2009 May;16(3):209-14 [19318941.001]
  • [Cites] J Cell Sci. 2009 Jun 1;122(Pt 11):1842-51 [19461074.001]
  • [Cites] Cell Adh Migr. 2009 Apr-Jun;3(2):199-204 [19363295.001]
  • [Cites] Cell Adh Migr. 2009 Apr-Jun;3(2):211-5 [19372738.001]
  • [Cites] Nat Rev Cancer. 2010 Jan;10(1):9-22 [20029421.001]
  • [Cites] Oncogene. 2010 Mar 4;29(9):1351-61 [20010874.001]
  • [Cites] Nat Genet. 2000 May;25(1):55-7 [10802656.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14720-5 [11121071.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):4956-60 [11431323.001]
  • [Cites] Mol Cell Neurosci. 2001 Jul;18(1):108-18 [11461157.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6674-8 [11559533.001]
  • [Cites] Development. 2002 Jun;129(12):2891-903 [12050137.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):269-77 [12086863.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5551-8 [12359767.001]
  • [Cites] Mol Cell Biol. 2002 Nov;22(21):7667-77 [12370313.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1962-8 [12702589.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2751-8 [15087390.001]
  • [Cites] Anal Biochem. 1994 Feb 1;216(2):276-84 [8179182.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2746-51 [7796398.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8502-7 [8710899.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8761-6 [9238051.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12081-7 [9342366.001]
  • [Cites] Brain Pathol. 1999 Jul;9(3):469-79 [10416987.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Development. 2005 Jan;132(1):165-76 [15576410.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):229-43 [15674480.001]
  • [Cites] Am J Pathol. 2005 Jun;166(6):1883-94 [15920172.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13479-83 [16157875.001]
  • [Cites] Curr Top Dev Biol. 2005;69:67-99 [16243597.001]
  • [Cites] Am J Pathol. 2005 Nov;167(5):1379-87 [16251422.001]
  • [Cites] J Neurosci. 2005 Oct 26;25(43):9940-8 [16251442.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • (PMID = 20531304.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NINDS NIH HHS / NS / R01 NS059876-03; United States / NINDS NIH HHS / NS / R01NS059876; United States / NCI NIH HHS / CA / P50CA127001; United States / NINDS NIH HHS / NS / R01 NS059876-02S2; United States / NINDS NIH HHS / NS / R01 NS059876; United States / NCI NIH HHS / CA / P50 CA127001; United States / NINDS NIH HHS / NS / NS059876-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Integrins; 0 / integrin alphavbeta8
  • [Other-IDs] NLM/ NIHMS198457; NLM/ PMC3037767
  •  go-up   go-down


99. Jackson EL, Alvarez-Buylla A: Characterization of adult neural stem cells and their relation to brain tumors. Cells Tissues Organs; 2008;188(1-2):212-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of adult neural stem cells and their relation to brain tumors.
  • The adult mammalian brain contains neural stem cells that are capable of generating new neurons and glia over the course of a lifetime.
  • Recent studies have shown that adult SVZ stem cells are derived from radial glia, the stem cells in the developing brain, which in turn are derived from the neuroepithelum, the earliest brain progenitors.
  • However, it seems that only a small subset of the astrocytes present in the adult brain have stem cell properties.
  • Intriguingly, activation of these same signaling pathways is widely implicated in brain tumor formation.
  • Since the adult brain has very few proliferating cells capable of accumulating the numerous mutations required for transformation, the adult neural stem and/or progenitor cells may be likely candidates for the brain tumor cell of origin.
  • Indeed, activation of the PDGF or epidermal growth factor pathways in adult neural stem or progenitor cells confers tumor-like properties on these cells, lending support to this hypothesis.
  • [MeSH-major] Adult Stem Cells / pathology. Brain Neoplasms / pathology. Neurons / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18223308.001).
  • [ISSN] 1422-6421
  • [Journal-full-title] Cells, tissues, organs
  • [ISO-abbreviation] Cells Tissues Organs (Print)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Number-of-references] 116
  •  go-up   go-down


100. Checrallah A, Geha S, Rizk T, Koussa S: [Multiple sclerosis mimicking brain tumor: an unusual presentation]. J Med Liban; 2005 Jan-Mar;53(1):45-9
MedlinePlus Health Information. consumer health - Multiple Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple sclerosis mimicking brain tumor: an unusual presentation].
  • There are, however, rare pseudo tumoral cases of MS with atypical clinical and imaging features that suggest initially a neoplastic or an infectious processes and in which a stereotactic brain biopsy becomes needed for the diagnosis.
  • Magnetic resonance imaging (MRI) of the brain showed a left contrast enhancing fronto-parietal mass lesion with important peripheral edema and displacement of the lateral ventricle.
  • The MRI at that time showed a marked decrease in size of the brain lesion.
  • The stereotactic brain biopsy remains to date the most dependable means for diagnosing the rare pseudotumoral forms of MS and differentiating them from their neoplastic and infectious mimickers.
  • [MeSH-major] Brain Neoplasms / diagnosis. Multiple Sclerosis / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Paresis

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16398212.001).
  • [ISSN] 0023-9852
  • [Journal-full-title] Le Journal médical libanais. The Lebanese medical journal
  • [ISO-abbreviation] J Med Liban
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Lebanon
  •  go-up   go-down






Advertisement